



深圳市海王英特龍 生物技術股份有限公司

SHENZHEN NEPTUNUS INTERLONG
BIO-TECHNIQUE COMPANY LIMITED*

(a joint stock limited company incorporated
in the People's Republic of China)

(於中華人民共和國註冊成立之股份有限公司)

Stock Code 股份代號：8329

* For identification purpose only 僅供識別之用



Interim Report

2021 中期報告



CHARACTERISTICS OF GEM OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE “STOCK EXCHANGE”)

GEM has been positioned as a market designed to accommodate small and mid-sized companies to which a higher investment risk may be attached than other companies listed on the Stock Exchange. Prospective investors should be aware of the potential risks of investing in such companies and should make the decision to invest only after due and careful consideration.

Given that the companies listed on GEM are generally small and mid-sized companies, there is a risk that securities traded on GEM may be more susceptible to high market volatility than securities traded on the Main Board and no assurance is given that there will be a liquid market in the securities traded on GEM.

Hong Kong Exchanges and Clearing Limited and the Stock Exchange take no responsibility for the contents of this report, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from, or in reliance upon the whole or any part of the contents of this report.

This report, for which the directors (the “Directors”) of Shenzhen Neptunus Interlong Bio-technique Company Limited (the “Company”) collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of the Stock Exchange (the “GEM Listing Rules”) for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this report is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this report misleading.

香港聯合交易所有限公司(「聯交所」)GEM的特色

GEM的定位，乃為中小型公司提供一個上市的市場，此等公司相比起其他在聯交所上市的公司帶有較高投資風險。有意投資的人士應了解投資於該等公司的潛在風險，並應經過審慎周詳的考慮後方可作出投資決定。

由於**GEM**上市公司普遍為中小型公司，在**GEM**買賣的證券可能會較於聯交所主板買賣之證券承受較大的市場波動風險，同時無法保證在**GEM**買賣的證券會有高流通量的市場。

香港交易及結算所有限公司及聯交所對本報告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本報告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。

本報告的資料乃遵照聯交所的《**GEM**證券上市規則》(「**GEM**上市規則」)而刊載，旨在提供有關深圳市海王英特龍生物技術股份有限公司(「本公司」)的資料。本公司的董事(「董事」)願就本報告的資料共同及個別地承擔全部責任。各董事在作出一切合理查詢後，確認就其所知及所信，本報告所載資料在各重要方面均屬準確完備，沒有誤導或欺詐成份，且並無遺漏任何事項，足以令致本報告或其所載任何陳述產生誤導。

INTERIM RESULTS (UNAUDITED)

The board of directors (the "Board") of the Company is pleased to present the unaudited condensed consolidated interim financial statements of the Company and its subsidiaries (collectively the "Group") for the six months ended 30 June 2021 (the "Reporting Period"), together with the unaudited comparative figures for the corresponding period of 2020.

中期業績(未經審核)

本公司董事會(「董事會」)欣然呈列本公司及其附屬公司(統稱「本集團」)截至二零二一年六月三十日止六個月(「報告期間」)之未經審核簡明綜合中期財務報表連同二零二零年同期之未經審核比較數字。

CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME (UNAUDITED)

簡明綜合損益及其他全面收益表(未經審核)

for the three months and six months ended 30 June 2021

截至二零二一年六月三十日止三個月及六個月

		For the three months ended 30 June 截至六月三十日止三個月		For the six months ended 30 June 截至六月三十日止六個月		
		2021 二零二一年 RMB'000 人民幣千元 (Unaudited) (未經審核)	2020 二零二零年 RMB'000 人民幣千元 (Unaudited) (未經審核)	2021 二零二一年 RMB'000 人民幣千元 (Unaudited) (未經審核)	2020 二零二零年 RMB'000 人民幣千元 (Unaudited) (未經審核)	
	Note 附註					
Revenue	收入	4	171,905	264,699	391,194	459,546
Cost of sales	銷售成本		(104,749)	(116,753)	(205,891)	(219,746)
Gross profit	毛利		67,156	147,946	185,303	239,800
Other revenue	其他收入	4	8,178	5,298	12,021	7,150
Other net income	其他收入淨額	4	1,631	1,798	2,318	2,214
Selling and distribution expenses	銷售及分銷開支		(44,059)	(111,030)	(121,177)	(168,634)
Administrative expenses	行政開支		(17,290)	(14,047)	(34,465)	(29,699)
Other operating expenses	其他經營開支		(11,169)	(20,273)	(17,230)	(28,015)
Profit from operations	經營溢利		4,447	9,692	26,770	22,816
Finance costs	財務成本	7(a)	(727)	(268)	(738)	(510)
Profit before taxation	除稅前溢利	7	3,720	9,424	26,032	22,306
Income tax credit/(expenses)	所得稅抵免/(開支)	8	892	53	(3,347)	(3,052)
Profit and total comprehensive income for the period	期內溢利及全面收益總額		4,612	9,477	22,685	19,254

CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME (UNAUDITED) (CONTINUED)

簡明綜合損益及其他全面收益表(未經審核)(續)

For the three months and six months ended 30 June 2021

截至二零二一年六月三十日止三個月及六個月

		For the three months ended 30 June		For the six months ended 30 June	
		截至六月三十日止三個月		截至六月三十日止六個月	
	Note	2021	2020	2021	2020
	附註	二零二一年	二零二零年	二零二一年	二零二零年
		RMB'000	RMB'000	RMB'000	RMB'000
		人民幣千元	人民幣千元	人民幣千元	人民幣千元
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
		(未經審核)	(未經審核)	(未經審核)	(未經審核)
Profit and total comprehensive income for the period attributable to:	以下各項應佔期內溢利及全面收益總額：				
Owners of the Company	本公司擁有人	3,999	8,932	19,647	18,250
Non-controlling interests	非控股權益	613	545	3,038	1,004
		4,612	9,477	22,685	19,254
Earnings per share for profit attributable to the owners of the Company during the period	期內本公司擁有人應佔溢利之每股盈利				
Basic and diluted	基本及攤薄	10			
		RMB0.24 cents	RMB0.53 cents	RMB1.17 cents	RMB1.09 cents
		人民幣0.24分	人民幣0.53分	人民幣1.17分	人民幣1.09分

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION (UNAUDITED)

簡明綜合財務狀況表(未經審核)

as at 30 June 2021

於二零二一年六月三十日

		Notes 附註	At 30 June 2021 於二零二一年 六月三十日 RMB'000 人民幣千元 (Unaudited) (未經審核)	At 31 December 2020 於二零二零年 十二月三十一日 RMB'000 人民幣千元 (Audited) (經審核)
ASSETS AND LIABILITIES	資產及負債			
Non-current assets	非流動資產			
Property, plant and equipment	物業、廠房及設備	11	238,074	158,788
Right-of-use assets	使用權資產		86,642	56,925
Goodwill	商譽		90,163	–
Intangible assets	無形資產		118,402	88,941
Deposits for acquisition of property, plant and equipment	購買物業、廠房及設備的按金		3,123	3,891
Deposit for acquisition of land use right	購買土地使用權的按金		9,817	–
Deferred tax assets	遞延稅項資產		2,769	2,986
			548,990	311,531
Current assets	流動資產			
Inventories	存貨		171,852	120,861
Trade and other receivables	應收賬款及其他應收款項	12	260,034	270,160
Pledged bank deposits	已抵押銀行存款		40	2,445
Short-term bank deposits	短期銀行存款		–	4,000
Tax recoverable	可收回稅項		3,103	–
Bank balances and cash	銀行結餘及現金		261,956	411,885
			696,985	809,351

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION (UNAUDITED) (CONTINUED)

簡明綜合財務狀況表(未經審核)(續)

as at 30 June 2021

於二零二一年六月三十日

		Notes 附註	At 30 June 2021 於二零二一年 六月三十日 RMB'000 人民幣千元 (Unaudited) (未經審核)	At 31 December 2020 於二零二零年 十二月三十一日 RMB'000 人民幣千元 (Audited) (經審核)
Current liabilities	流動負債			
Trade and other payables	應付賬款及其他應付款項	14	244,388	179,509
Contract liabilities	合約負債		13,177	16,345
Interest-bearing bank borrowings	付息銀行借貸	15	40,000	–
Entrusted loan from the immediate parent company	直屬母公司委託借款	19(b)	–	9,000
Deferred revenue	遞延收入		5,118	401
Lease liabilities	租賃負債	16	759	1,059
Current taxation	即期稅項		7,216	5,953
			310,658	212,267
Net current assets	流動資產淨值		386,327	597,084
Total assets less current liabilities	總資產減流動負債		935,317	908,615
Non-current liabilities	非流動負債			
Other payables	其他應付款項	14	1,844	–
Deferred revenue	遞延收入		1,191	1,441
Deferred tax liabilities	遞延稅項負債		27,051	11,502
			30,086	12,943
Net assets	資產淨值		905,231	895,672

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION (UNAUDITED) (CONTINUED)

簡明綜合財務狀況表(未經審核)(續)

as at 30 June 2021

於二零二一年六月三十日

		Notes 附註	At 30 June 2021 於二零二一年 六月三十日 RMB'000 人民幣千元 (Unaudited) (未經審核)	At 31 December 2020 於二零二零年 十二月三十一日 RMB'000 人民幣千元 (Audited) (經審核)
EQUITY	權益			
Equity attributable to owners of the Company	本公司擁有人應佔權益			
Share capital	股本		167,800	167,800
Reserves	儲備		645,585	625,938
Total	總計		813,385	793,738
Non-controlling interests	非控股權益		91,846	101,934
Total equity	權益總額		905,231	895,672

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (UNAUDITED)

簡明綜合權益變動表(未經審核)

for the six months ended 30 June 2021

截至二零二一年六月三十日止六個月

		Attributable to owners of the Company 本公司擁有人應佔							
		Share capital 股本	Share premium 股份溢價	Capital reserve 資本儲備	Statutory reserve fund 法定公積金	Retained earnings 保留盈利	Sub-total 小計	Non-controlling interests 非控股權益	Total 總計
		RMB'000 人民幣千元	RMB'000 人民幣千元	RMB'000 人民幣千元	RMB'000 人民幣千元	RMB'000 人民幣千元	RMB'000 人民幣千元	RMB'000 人民幣千元	RMB'000 人民幣千元
At 1 January 2020 (audited)	於二零二零年一月一日(經審核)	167,800	554,844	(188,494)	48,465	174,531	757,146	102,784	859,930
Change in equity for 2020	二零二零年權益變動								
Profit and total comprehensive income for the period	期內溢利及全面收益總額	-	-	-	-	18,250	18,250	1,004	19,254
Dividend paid from a subsidiary to non-controlling interests	派付非控股權益的附屬公司股息	-	-	-	-	-	-	(3,000)	(3,000)
At 30 June 2020 (unaudited)	於二零二零年六月三十日(未經審核)	167,800	554,844	(188,494)	48,465	192,781	775,396	100,788	876,184
At 1 January 2021 (audited)	於二零二一年一月一日(經審核)	167,800	554,844	(188,494)	48,936	210,652	793,738	101,934	895,672
Change in equity for 2021	二零二一年權益變動								
Profit and total comprehensive income for the period	期內溢利及全面收益總額	-	-	-	-	19,647	19,647	3,038	22,685
Acquisition of a subsidiary (note 17)	收購一間附屬公司(附註17)	-	-	-	-	19,647	19,647	3,038	22,685
		-	-	-	-	-	-	(13,126)	(13,126)
At 30 June 2021 (unaudited)	於二零二一年六月三十日(未經審核)	167,800	554,844	(188,494)	48,936	230,299	813,385	91,846	905,231

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (UNAUDITED)

簡明綜合現金流量表(未經審核)

for the six months ended 30 June 2021

截至二零二一年六月三十日止六個月

For the six months ended 30 June

截至六月三十日止六個月

		2021 二零二一年 RMB'000 人民幣千元 (Unaudited) (未經審核)	2020 二零二零年 RMB'000 人民幣千元 (Unaudited) (未經審核)
Operating profit before changes in working capital	營運資金變動前之經營盈利	37,856	45,970
Changes in working capital	營運資金變動		
(Increase)/Decrease in inventories	存貨(增加)/減少	(5,116)	10,398
Decrease in trade and other receivables	應收賬款及其他應收款項減少	39,429	69,483
Decrease in pledged bank deposits	已抵押銀行存款減少	2,405	-
Decrease in trade and other payables and contract liabilities	應付賬款及其他應付款項以及合約負債減少	(141,704)	(43,019)
Increase in deferred revenue	遞延收入增加	4,467	-
Cash (used in)/generated from operations	經營(所用)/產生現金	(62,663)	82,832
Income tax paid – The People's Republic of China	已繳所得稅—中華人民共和國	(2,373)	(11,978)
Net cash (used in)/generated from operating activities	經營活動(所用)/產生現金淨額	(65,036)	70,854
Investing activities	投資活動		
Net cash outflow on acquisition of a subsidiary	收購一間附屬公司現金流出淨額	(63,683)	-
Deposits for acquisition of property, plant and equipment	購置物業、廠房及設備的按金	(6,873)	(10,318)
Additions to intangible assets	添置其他無形資產	(2,211)	(821)
Payment for purchase of property, plant and equipment	購置物業、廠房及設備的付款	(598)	(6,342)
Proceeds from disposal of property, plant and equipment	出售物業、廠房及設備的所得款項	20	-
Placement of principal protected deposits	存放保本型存款	(90,000)	(212,550)
Receipts from principal protected deposits	保本型存款的收款	90,000	-
Decrease in short-term bank deposits	短期銀行存款減少	4,000	-
Interest received	已收利息	4,933	2,506
Net cash used in investing activities	投資活動所用現金淨額	(64,412)	(227,525)

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (UNAUDITED) (CONTINUED)

簡明綜合現金流量表(未經審核)(續)

For the six months ended 30 June 2021
截至二零二一年六月三十日止六個月

For the six months ended 30 June
截至六月三十日止六個月

		2021 二零二一年 RMB'000 人民幣千元 (Unaudited) (未經審核)	2020 二零二零年 RMB'000 人民幣千元 (Unaudited) (未經審核)
Financing activities	籌資活動		
Repayment of interest-bearing borrowings	償還計息借款	(10,000)	(30,000)
Proceeds from interest-bearing borrowings	計息借款所得款項	-	30,000
Repayment of entrusted loan from the immediate parent company	償還直屬母公司委託借款	(9,000)	-
Interest paid	已付利息	(712)	(510)
Dividend paid to non-controlling interests	派付非控股權益的股息	-	(3,000)
Payment of lease liabilities	結算租賃負債	(769)	-
Net cash used in financing activities	籌資活動所用現金淨額	(20,481)	(3,510)
Net decrease in cash and cash equivalents	現金及現金等價物減少淨額	(149,929)	(160,181)
Cash and cash equivalents at the beginning of the period	於期初的現金及現金等價物	411,885	384,211
Cash and cash equivalents at the end of the period	於期末的現金及現金等價物	261,956	224,030
Analysis of cash and cash equivalents at 30 June	於六月三十日的現金及現金等價物分析		
Bank balances and cash	銀行結餘及現金	261,956	224,030

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL REPORT

for the six months ended 30 June 2021

1. CORPORATE INFORMATION

The Company is a joint stock limited company registered in the People's Republic of China (the "PRC"). The registered office of the Company is Suite 2103, 21st Floor, Neptunus Yinhe Technology Mansion, 1 Keji Middle 3rd Road, Yuehai Sub-district, Nanshan District, Shenzhen, Guangdong Province, the PRC.

2. BASIS OF PREPARATION AND ACCOUNTING POLICIES

The condensed consolidated interim financial statements for the six months ended 30 June 2021 have been prepared in accordance with the applicable disclosure provision of the GEM Listing Rules on the Stock Exchange, including compliance with Hong Kong Accounting Standard ("HKAS") 34, "Interim Financial Reporting" issued by the Hong Kong Institute of Certified Public Accountants ("HKICPA").

The preparation of the condensed consolidated interim financial statements in conformity with HKAS 34 requires the management to make judgements, estimates and assumptions that affect the application of policies and the reported amounts of assets and liabilities, income and expenses on a year to date basis. Actual results may differ from these estimates.

The condensed consolidated interim financial statements have been prepared in accordance with the same accounting policies adopted in the annual financial statements for the year ended 31 December 2020. The condensed consolidated interim financial statements do not include all the information and disclosures required for annual financial statements, and should be read in conjunction with the financial statements of the Group for the year ended 31 December 2020.

This condensed consolidated interim financial statements for the period ended 30 June 2021 comprises the Company and its subsidiaries.

簡明綜合中期財務報表附註

截至二零二一年六月三十日止六個月

1. 公司資料

本公司為一家在中華人民共和國(「中國」)註冊的股份有限公司。本公司註冊辦事處位於中國廣東省深圳市南山區粵海街道科技中三路1號海王銀河科技大廈21樓2103室。

2. 編製基準及會計政策

截至二零二一年六月三十日止六個月之簡明綜合中期財務報表已根據聯交所GEM上市規則之適用披露條文編製，包括遵守香港會計師公會(「香港會計師公會」)所頒佈之香港會計準則(「香港會計準則」)第34號「中期財務報告」。

編製符合香港會計準則第34號之簡明綜合中期財務報表要求管理層作出影響政策應用及按本年截至公告日期為止資產及負債、收入及開支申報數額之判斷、估計及假設。實際結果可能與該等估計有所不同。

簡明綜合中期財務報表已按照與截至二零二零年十二月三十一日止年度之年度財務報表所採納之相同會計政策編製。簡明綜合中期財務報表並無載列年度財務報表要求之所有資料及披露事項，並須與截至二零二零年十二月三十一日止年度之本集團財務報表一併閱讀。

截至二零二一年六月三十日止期間的簡明綜合中期財務報表包括本公司及其附屬公司。

2. BASIS OF PREPARATION AND ACCOUNTING POLICIES (CONTINUED)

The measurement basis used in the preparation of these financial statements is the historical cost basis. These financial statements are presented in Renminbi (“RMB”), which is also the functional currency of the Company and all amounts are rounded to the nearest thousand except where otherwise indicated.

The condensed consolidated interim financial statements are unaudited.

3. ADOPTION OF NEW AND AMENDED HKFRSs

(a) Adoption of new or revised HKFRSs effective on 1 January 2021

During the Reporting Period, the Group has applied for the first time the following amended HKFRSs issued by the HKICPA, which are relevant to the Group’s operations and effective for the Group’s consolidated financial statements for the annual period beginning on 1 January 2021:

Amendment to HKFRS 16	Covid-19-Related Rent Concessions
Amendments to HKFRS 9, HKAS 39, HKFRS 7, HKFRS 4 and HKFRS 16	Interest Rate Benchmark Reform – Phase 2

The adoption of the above amended HKFRSs had no material impact on and the Group’s financial position for the current and prior periods have been prepared and presented.

(b) Issued but not yet effective HKFRSs

At the date of authorisation of the Group’s condensed consolidated interim financial statements, certain new and amended HKFRSs have been published but are not yet effective, and have not been adopted early by the Group.

2. 編製基準及會計政策(續)

編製財務報表時所使用的計量基準為歷史成本基準。財務報表乃以人民幣(「人民幣」)呈列，而人民幣亦為本公司的功能貨幣，除另有指明外，所有金額均以四捨五入方式約整至最接近的千位數。

本簡明綜合中期財務報表未經審核。

3. 採納新訂及經修訂香港財務報告準則

(a) 採納於二零二一年一月一日開始生效之新訂立或經修訂香港財務報告準則

於本報告期間，本集團已首次採用下列由香港會計師公會頒佈與本集團營運有關且於本集團於二零二一年一月一日開始之年度期間之綜合財務報表生效之新訂及經修訂香港財務報告準則：

香港財務報告準則第16號(修訂本)	新冠病毒疫情相關租金寬減
香港財務報告準則第9號、香港會計準則第39號、香港財務報告準則第7號、香港財務報告準則第4號及香港財務報告準則第16號(修訂本)	利率基準改革 – 第二階段

採納上述經修訂香港財務報告準則對本集團已編製及呈報的本期間及過往期間的財務狀況並無重大影響。

(b) 已發行但尚未生效的香港財務報告準則

在批准本集團之簡明綜合中期財務報表當日，若干新訂及經修訂香港財務報告準則已頒佈但仍未生效，本集團並沒有提早採納該等準則。

3. ADOPTION OF NEW AND AMENDED HKFRSs (CONTINUED)

(b) Issued but not yet effective HKFRSs (Continued)

HKFRS 17	Insurance Contracts and related amendments
Amendments to HKFRS 3	Reference to the Conceptual Framework
Amendments to HKFRS 10 and HKAS 28	Sale or Contribution of Assets between an Investor and its Associate or Joint Venture
Amendments to HKFRS 16	Covid-19-Related Rent Concessions beyond 30 June 2021
Amendments to HKAS 1	Classification of Liabilities as Current or Non-current and related amendments to Hong Kong Interpretation 5 (2020)
Amendments to HKAS 1 and HKFRS Practice Statement 2	Disclosure of Accounting Policies
Amendments to HKAS 8	Definition of Accounting Estimates
Amendments to HKAS 12	Deferred Tax related to Assets and Liabilities arising from a Single Transaction
Amendments to HKAS 16	Property, Plant and Equipment – Proceeds before Intended Use
Amendments to HKAS 37	Onerous Contracts – Cost of Fulfilling a Contract
Amendments to HKFRSs	Annual Improvements to HKFRS Standards 2018-2020
Accounting Guideline 5 (Revised)	Merger Accounting for Common Control Combination

The directors are currently assessing the possible impact of these new and amended standards on the Group's results and financial position in the first year of application. The directors consider that these amendments are unlikely to have a material impact to the Group's consolidated financial statements.

3. 採納新訂及經修訂香港財務報告準則(續)

(b) 已發行及未生效的香港財務報告準則(續)

香港財務報告準則第17號	保險合約及相關修訂
香港財務報告準則第3號(修訂本)	對框架概念的提述
香港財務報告準則第10號及香港會計準則第28號(修訂本)	投資者及其聯營公司或合資企業間出售或注入資產
香港財務報告準則第16號(修訂本)	二零二一年六月三十日之後的新冠病毒疫情相關租金寬減
香港會計準則第1號(修訂本)	香港詮釋第5號(2020)有關流動或非流動負債分類及相關修訂本
香港會計準則第1號及香港財務報告準則作業準則第2號(修訂本)	會計政策的披露
香港會計準則第8號(修訂本)	會計估計的定義
香港會計準則第12號(修訂本)	與單一交易產生的資產及負債相關的遞延稅項
香港會計準則第16號(修訂本)	物業、廠房及設備—於作擬定用途前之所得款項
香港會計準則第37號(修訂本)	有償合約—履行合約之成本
香港財務報告準則(修訂本)	香港財務報告準則二零一八年至二零二零年週期之年度改進
會計指引5(經修訂)	共同控制合併的合併會計

目前董事正在評估該等新訂及經修訂準則於首年應用中可能對本集團業績及財務狀況帶來的影響。董事認為該等修訂不太可能對本集團之綜合財務報表產生重大影響。

4. REVENUE AND OTHER REVENUE

Revenue arises mainly from manufacturing and selling of medicines and the sales and distribution of medicines and healthcare products.

4. 收入及其他收入

收入主要來自生產及銷售藥品以及銷售及分銷藥品及保健品。

		For the three months ended 30 June		For the six months ended 30 June	
		截至六月三十日止三個月		截至六月三十日止六個月	
		2021	2020	2021	2020
		二零二一年	二零二零年	二零二一年	二零二零年
		RMB'000	RMB'000	RMB'000	RMB'000
		人民幣千元	人民幣千元	人民幣千元	人民幣千元
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
		(未經審核)	(未經審核)	(未經審核)	(未經審核)
Revenue	收入				
Manufacturing and selling of medicines	生產及銷售藥品	111,977	112,717	233,766	199,482
Sales and distribution of medicines and healthcare products	銷售及分銷藥品及保健品	59,928	151,982	157,428	260,064
		171,905	264,699	391,194	459,546

4. REVENUE AND OTHER REVENUE (CONTINUED)

4. 收入及其他收入(續)

		For the three months ended 30 June 截至六月三十日止三個月		For the six months ended 30 June 截至六月三十日止六個月	
		2021 二零二一年 RMB'000 人民幣千元 (Unaudited) (未經審核)	2020 二零二零年 RMB'000 人民幣千元 (Unaudited) (未經審核)	2021 二零二一年 RMB'000 人民幣千元 (Unaudited) (未經審核)	2020 二零二零年 RMB'000 人民幣千元 (Unaudited) (未經審核)
Other revenue	其他收入				
Interest income from bank deposits	銀行存款利息收入	977	807	2,530	1,419
Interest income from principal protected deposits	保本型存款利息收入	1,399	976	2,403	1,087
Change in fair value of financial assets through profit or loss – principal protected deposit	計入損益之金融資產公平值變動－保本型存款	–	1,595	–	2,550
Agency fee income	代理費收入	4,717	–	4,717	–
Government subsidies	政府補貼				
– released from deferred revenue	– 轉撥自遞延收入	99	99	249	199
– directly recognised in profit or loss	– 直接計入損益	671	1,750	1,507	1,760
Others	其他	315	71	615	135
		8,178	5,298	12,021	7,150
Other net income	其他收入淨額				
Reversal of impairment loss on trade and other receivables	應收賬款及其他應收款項減值虧損撥回	399	284	779	284
Reversal of write down of inventories (Note)	存貨撇減撥回(附註)	(77)	253	230	669
Reversal of provision for estimated loss from legal proceedings	法律訴訟後估計虧損沖回	1,282	–	1,282	–
Net foreign exchange gains	匯兌收益淨額	27	32	27	32
Gain on disposal of property, plant and equipment	出售物業、廠房及設備的收益	–	330	–	330
Others	其他	–	899	–	899
		1,631	1,798	2,318	2,214

Note:

During the period, the reversal of write down of inventories is mainly due to the inventories' expiration date has expired, therefore the provision of impairment of inventories made in prior years has been reversed.

Therefore, a reversal of write down of inventories of approximately RMB230,000 (six-month period ended 30 June 2020: approximately RMB669,000) was recognised in the condensed consolidated statement of profit or loss and other comprehensive income.

附註：

於報告期間，存貨撇減撥回主要由於存貨過期，因此以往年度的存貨減值撥備已於本期撥回。

因此，存貨撇減撥回約人民幣230,000元(截至二零二零年六月三十日止六個月期間：約人民幣669,000元)已於簡明綜合損益及其他全面收益表確認。

5. SEGMENT REPORTING

The Group manages its business by divisions, which are organised by a mixture of both business lines (products and services) and geographical location. In a manner consistent with the way in which information is reported internally to the Group's executive directors, being the chief operation decision maker, for the purpose of resources allocation and performance assessment, the Group has presented the following two reportable segments. No operating segments have been aggregated to form the following reportable segments.

- (i) Manufacturing and selling of medicines; and
- (ii) Sales and distribution of medicines and healthcare products.

Currently all the Group's activities above are carried out in the PRC. No reportable operating segment has been aggregated.

The first segment derives its revenue from the manufacture and sales of medicines and medical devices.

The second segment derives its revenue from sales and distribution of medicines and healthcare products.

(a) Segment results, assets and liabilities

For the purposes of assessing segment performance and allocating resources between segments, the Group's executive directors monitor the results, assets and liabilities attributable to each reportable segment on the following bases:

Segment assets include current assets and non-current assets with the exception of tax recoverable and deferred tax assets. Segment liabilities include all current and non-current liabilities with the exception of current taxation and deferred tax liabilities.

5. 分部呈報

本集團按分部管理其業務，分部按兩條業務線（產品及服務）配合地理位置而組織。該等資料向本集團的執行董事（最高營運決策者）作內部報告以分配資源及作表現評估，本集團已呈列下列兩個可申報分部。並無匯總任何經營分部以構成下列可申報分部。

- (i) 生產及銷售藥品；及
- (ii) 銷售及分銷藥品及保健品。

目前，上述所有本集團業務均在中國營運。並無匯總任何可申報經營分部。

第一分部的收入來自生產及銷售藥品及醫療器械。

第二分部的收入來自銷售及分銷藥品及保健品。

(a) 分部業績、資產及負債

就評估分部表現及分部間分配資源而言，本集團的執行董事按以下基礎監控各可申報分部應佔的業績、資產及負債：

分部資產包括流動資產及非流動資產，但不包括可收回稅項及遞延稅項資產。分部負債包括所有流動及非流動負債，但不包括即期稅項及遞延所得稅負債。

5. SEGMENT REPORTING (CONTINUED)

(a) Segment results, assets and liabilities (Continued)

Revenue and expenses are allocated to the reportable segments with reference to sales generated by those segments and the expenses incurred by those segments or which otherwise arise from the depreciation or amortisation of assets attributable to those segments.

The measure used for reporting segments profit is “adjusted EBT”, i.e. “adjusted earnings before taxes”. To arrive at adjusted EBT, the Group’s earnings are further adjusted for items not specifically attributed to individual segments, such as directors’ fees and auditor’s remuneration and other head office or corporate administration costs.

In addition to receiving segment information concerning adjusted EBT, the executive directors are provided with segment information concerning revenue (including inter-segment revenue), impairment of trade and other receivables, reversal of impairment loss on trade and other receivables, write down of inventories and reversal of write down of inventories. Inter-segment revenue are priced with reference to prices charged to external parties for similar orders.

Information regarding the Group’s reportable segments as provided to the Group’s executive directors for the purposes of resources allocation and assessment of segment performance for the period ended 30 June 2021 and 30 June 2020 is set out below:

5. 分部呈報(續)

(a) 分部業績、資產及負債(續)

收入及開支乃經參考有關分部產生的銷售額及有關分部產生的開支或有關分部應佔資產的折舊或攤銷所產生的開支後分配至各可申報分部。

用於可申報分部溢利的方法為「經調整EBT」，即「扣除稅項前之經調整溢利」。為達到經調整EBT，本集團之盈利就並未歸屬至個別分部之項目作出進一步調整，如董事薪酬及核數師之費用以及其他總辦事處或公司行政開支。

除收到有關經調整EBT之分部資料外，執行董事獲提供有關收入(包括分部間收入)、應收賬款及其他應收款項的減值虧損、應收賬款及其他應收款項的減值虧損撥回，撇減存貨及存貨撇減撥回的分部資料。分部間收入乃經參考外部人士就類似訂單作出的價格而進行定價。

就資源分配及評估分部表現向本集團執行董事提供有關本集團可申報分部截至二零二一年六月三十日及二零二零年六月三十日止期間之資料載列如下：

5. SEGMENT REPORTING (CONTINUED)

(a) Segment results, assets and liabilities (Continued)

For the six months ended 30 June 截至六月三十日止六個月		Manufacturing and selling of medicines 生產及銷售藥品		Sales and distribution of medicines and healthcare products 銷售及分銷藥品及保健品		Total 總計	
		2021 二零二一年 RMB'000 人民幣千元 (Unaudited) (未經審核)	2020 二零二零年 RMB'000 人民幣千元 (Unaudited) (未經審核)	2021 二零二一年 RMB'000 人民幣千元 (Unaudited) (未經審核)	2020 二零二零年 RMB'000 人民幣千元 (Unaudited) (未經審核)	2021 二零二一年 RMB'000 人民幣千元 (Unaudited) (未經審核)	2020 二零二零年 RMB'000 人民幣千元 (Unaudited) (未經審核)
Segment revenue	分部收入						
Revenue from external customers	外來客戶收入	233,766	199,482	157,428	260,064	391,194	459,546
Inter-segment revenue	分部間收入	15,167	13,392	5,742	-	20,909	13,392
Reportable segment revenue	可申報分部收入	248,933	212,874	163,170	260,064	412,103	472,938
Reportable segment profit (adjusted EBT)	可申報分部溢利 (經調整EBT)	22,604	3,070	3,787	20,295	26,391	23,365
Impairment of:	減值：						
- trade receivables	- 應收賬款	(147)	(186)	(320)	(434)	(467)	(620)
- other receivables	- 其他應收款項	(18)	(124)	(1,042)	-	(1,060)	(124)
Reversal of impairment loss on:	減值虧損撥回：						
- trade receivables	- 應收賬款	111	2	529	278	640	280
- other receivables	- 其他應收款項	96	-	43	4	139	4
Write down of inventories	撇減存貨	(799)	(217)	(372)	(1,316)	(1,171)	(1,533)
Reversal of write down of inventories	存貨撇減撥回	-	367	230	302	230	669
Reversal of provision for estimated loss from legal proceedings	法律訴訟後估計虧損沖回	(1,282)	-	-	-	(1,282)	-
Income tax (expense)/credit	所得稅(開支)/抵免	(2,597)	2,453	(750)	(5,505)	(3,347)	(3,052)

5. 分部呈報(續)

(a) 分部業績、資產及負債(續)

5. SEGMENT REPORTING (CONTINUED)

(a) Segment results, assets and liabilities (Continued)

		Manufacturing and selling of medicines 生產及銷售藥品		Sales and distribution of medicines and healthcare products 銷售及分銷藥品及保健品		Total 總計	
		30 June 2021 二零二一年 六月三十日 RMB'000 人民幣千元 (Unaudited) (未經審核)	31 December 2020 二零二零年 十二月三十一日 RMB'000 人民幣千元 (Audited) (經審核)	30 June 2021 二零二一年 六月三十日 RMB'000 人民幣千元 (Unaudited) (未經審核)	31 December 2020 二零二零年 十二月三十一日 RMB'000 人民幣千元 (Audited) (經審核)	30 June 2021 二零二一年 六月三十日 RMB'000 人民幣千元 (Unaudited) (未經審核)	31 December 2020 二零二零年 十二月三十一日 RMB'000 人民幣千元 (Audited) (經審核)
Reportable segment assets	可申報分部資產	861,621	737,031	532,087	514,967	1,393,708	1,251,998
Additions to non-current segment assets (other than deferred tax assets) during the period/year	期內/年內新增非流動 可申報分部資產 (除遞延稅項資產外)	30,995	31,712	14,759	3,422	45,754	35,134
Reportable segment liabilities	可申報分部負債	415,443	247,642	37,345	95,566	452,788	343,208

5. 分部呈報(續)

(a) 分部業績、資產及負債(續)

5. SEGMENT REPORTING (CONTINUED)

(b) Reconciliations of reportable segment revenue, profit or loss, assets and liabilities

		Six months ended 30 June 截至六月三十日止六個月	
		2021 二零二一年 RMB'000 人民幣千元 (Unaudited) (未經審核)	2020 二零二零年 RMB'000 人民幣千元 (Unaudited) (未經審核)
Revenue	收入		
Reportable segment revenue	可申報分部收入	412,103	472,938
Elimination of inter-segment revenue	分部間收入抵銷	(20,909)	(13,392)
Consolidated revenue	綜合收入	391,194	459,546
Profit	溢利		
Reportable segment profit	可申報分部溢利	26,391	23,365
Elimination of inter-segment profit	分部間溢利抵銷	(170)	(298)
Reportable segment profit derived from the Group's external customers	來自本集團外來客戶的可申報分部溢利	26,221	23,067
Unallocated head office and corporate expenses	未分配總部及企業開支	(189)	(761)
Consolidated profit before taxation	除稅前綜合溢利	26,032	22,306

5. 分部呈報(續)

(b) 可申報分部收入、損益、資產及負債的對賬

5. SEGMENT REPORTING (CONTINUED)

(b) Reconciliations of reportable segment revenue, profit or loss, assets and liabilities (Continued)

		At 30 June 2021 二零二一年 六月三十日 RMB'000 人民幣千元 (Unaudited) (未經審核)	At 31 December 2020 二零二零年 十二月三十一日 RMB'000 人民幣千元 (Audited) (經審核)
Assets	資產		
Reportable segment assets	可申報分部資產	1,393,708	1,251,998
Elimination of inter-segment receivables	分部間應收款項抵銷	(153,605)	(134,102)
		1,240,103	1,117,896
Tax recoverable	可收回稅項	3,103	-
Deferred tax assets	遞延稅項資產	2,769	2,986
Consolidated total assets	綜合資產總額	1,245,975	1,120,882
Liabilities	負債		
Reportable segment liabilities	可申報分部負債	452,788	343,208
Elimination of inter-segment payables	分部間應付款項抵銷	(146,311)	(135,453)
		306,477	207,755
Current taxation	即期稅項	7,216	5,953
Deferred tax liabilities	遞延稅項負債	27,051	11,502
Consolidated total liabilities	綜合負債總額	340,744	225,210

5. 分部呈報(續)

(b) 可申報分部收入、損益、資產及負債的對賬(續)

5. SEGMENT REPORTING (CONTINUED)

(c) Disaggregation of revenue from contracts with customers

The Group derives revenue from sales of medicines and healthcare products, medical devices and sales management services of pharmaceutical products at a point in time in type of customer:

		Hospital 醫院 RMB'000 人民幣千元 (Unaudited) (未經審核)	Pharmacy 藥房 RMB'000 人民幣千元 (Unaudited) (未經審核)	Others 其他 RMB'000 人民幣千元 (Unaudited) (未經審核)	Total 總計 RMB'000 人民幣千元 (Unaudited) (未經審核)
At 30 June 2021	於二零二一年六月三十日				
Manufacturing and selling of medicines	生產及銷售藥品	34,880	196,443	2,443	233,766
Sales and distribution of medicines and healthcare products	銷售及分銷藥品及保健品	23,855	133,573	–	157,428
		58,735	330,016	2,443	391,194
		Hospital 醫院 RMB'000 人民幣千元 (Unaudited) (未經審核)	Pharmacy 藥房 RMB'000 人民幣千元 (Unaudited) (未經審核)	Others 其他 RMB'000 人民幣千元 (Unaudited) (未經審核)	Total 總計 RMB'000 人民幣千元 (Unaudited) (未經審核)
At 30 June 2020	於二零二零年六月三十日				
Manufacturing and selling of medicines	生產及銷售藥品	28,427	166,435	4,620	199,482
Sales and distribution of medicines and healthcare products	銷售及分銷藥品及保健品	751	259,313	–	260,064
		29,178	425,748	4,620	459,546

5. 分部呈報(續)

(c) 細分來自客戶合約的收入

本集團於某一時間點按客戶類別劃分的來自銷售藥品及保健品、醫療器械及藥品銷售管理服務的收入：

6. SEASONALITY OF OPERATIONS

(a) Revenue from major products and services

The Group's business in the manufacturing and selling of medicines and sales and distribution of medicines and healthcare products had no specific seasonality factor, and analysed as follows:

Medicines and healthcare products	藥品及保健品銷售
Sales of medical devices	醫療器械銷售
Sales management services of pharmaceutical products	藥品銷售管理服務

(b) Geographical information

The Group's revenue and results from operations mainly derived from activities in the PRC. The principal assets of the Group were located in the PRC during the period/year. Accordingly, no analysis by geographical segment is provided.

6. 營運季節性

(a) 來自主要產品及服務的收入

本集團生產及銷售藥品以及銷售及分銷藥品及保健品之業務並無特定季節性因素，其分析如下：

Six months ended 30 June

截至六月三十日止六個月

2021 二零二一年 RMB'000 人民幣千元 (Unaudited) (未經審核)	2020 二零二零年 RMB'000 人民幣千元 (Unaudited) (未經審核)
364,720	424,390
26,474	34,405
—	751
391,194	459,546

(b) 地理資料

本集團的收入及經營業績主要來自中國的業務活動。於期間／年內，本集團的主要資產位於中國。因此，概無提供地理分部分析。

7. PROFIT BEFORE TAXATION

Profit before taxation is arrived at after (crediting)/charging the following:

7. 除稅前溢利

除稅前溢利乃經(抵免)/扣除如下：

		For the three months ended 30 June		For the six months ended 30 June	
		截至六月三十日止三個月		截至六月三十日止六個月	
		2021	2020	2021	2020
		二零二一年	二零二零年	二零二一年	二零二零年
		RMB'000	RMB'000	RMB'000	RMB'000
		人民幣千元	人民幣千元	人民幣千元	人民幣千元
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
		(未經審核)	(未經審核)	(未經審核)	(未經審核)
(a) Finance costs	(a) 財務費用				
Interest on bank loans	銀行貸款利息	712	268	712	510
Interest on lease liabilities	租賃負債利息	15	–	26	–
		727	268	738	510
(b) Staff costs (including directors' emoluments)	(b) 員工成本(包括董事酬金)				
Salaries, wages and other benefits	薪金、工資及其他福利	28,492	21,982	50,695	43,476
Contributions to defined contribution retirement plans	定額供款退休計劃的供款	4,353	780	8,382	3,480
		32,845	22,762	59,077	46,956
(c) Other items	(c) 其他項目				
Depreciation of right-of-use assets	使用權資產折舊	1,019	392	1,601	785
Amortisation of intangible assets (Note 1)	無形資產攤銷(附註1)	1,763	1,042	2,748	2,068
Depreciation of property, plant and equipment	物業、廠房及設備折舊	6,109	4,381	10,132	8,425
Cost of inventories	存貨成本	88,247	115,094	187,356	216,011
Research & development costs	研發費用	6,082	4,865	11,402	10,375

7. PROFIT BEFORE TAXATION (CONTINUED)

7. 除稅前溢利(續)

	For the three months ended 30 June 截至六月三十日止三個月		For the six months ended 30 June 截至六月三十日止六個月	
	2021 二零二一年 RMB'000 人民幣千元 (Unaudited) (未經審核)	2020 二零二零年 RMB'000 人民幣千元 (Unaudited) (未經審核)	2021 二零二一年 RMB'000 人民幣千元 (Unaudited) (未經審核)	2020 二零二零年 RMB'000 人民幣千元 (Unaudited) (未經審核)
Impairment of:				
– trade receivables (Note 1)	317	612	467	620
– other receivables (Note 1)	1,060	101	1,060	124
Impairment loss on intangible assets (Note 1)	–	–	–	13,588
Loss on disposal of property, plant and equipment (Note 1)	15	(64)	1	14
Write down of inventories (Note 1 & 2)	277	909	1,171	1,533
Auditor's remuneration	–	–	–	–
Auditor's non-audit services remuneration	106	220	189	252
Lease charges				
– Short-term leases	980	1,031	2,623	2,424
Reversal of provision for estimated loss from legal proceedings	–	–	(1,282)	–

Notes:

- These amounts have been included in "Other operating expenses" in the condensed consolidated statement of profit or loss and other comprehensive income.
- As at 30 June 2021, write down of inventories was approximately RMB1,171,000 (six-month period ended 30 June 2020: approximately RMB1,533,000) were identified and recognised in the condensed consolidated statement of profit or loss and other comprehensive income.

附註:

- 此等金額已計入簡明綜合損益及其他全面收益表的「其他經營開支」內。
- 於二零二一年六月三十日，撇減存貨約人民幣1,171,000元(截至二零二零年六月三十日止六個月期間：約人民幣1,533,000元)已獲識別及於簡明綜合損益及其他全面收益表確認。

8. INCOME TAX CREDIT/EXPENSES

Income tax (credit)/expenses in the condensed consolidated statement of profit or loss and other comprehensive income represents:

8. 所得稅抵免／開支

於簡明綜合損益及其他全面收益表列出的所得稅(抵免)／開支指：

		For the three months ended 30 June 截至六月三十日止三個月		For the six months ended 30 June 截至六月三十日止六個月	
		2021 二零二一年 RMB'000 人民幣千元 (Unaudited) (未經審核)	2020 二零二零年 RMB'000 人民幣千元 (Unaudited) (未經審核)	2021 二零二一年 RMB'000 人民幣千元 (Unaudited) (未經審核)	2020 二零二零年 RMB'000 人民幣千元 (Unaudited) (未經審核)
Current tax	即期稅項				
Provision for PRC Enterprise Income Tax ("EIT")	中國企業所得稅撥備 (「企業所得稅」)	(869)	3,381	3,465	6,679
Deferred tax	遞延稅項				
Origination and reversal of temporary differences	暫時性差額的衍生及撥回	(23)	(3,434)	(118)	(3,627)
		(892)	(53)	3,347	3,052

Hong Kong Profits Tax has not been provided for as the Group had no assessable profit to Hong Kong Profits Tax during the Reporting Period (30 June 2020: Nil).

As at 30 June 2021, three subsidiaries (30 June 2020: two subsidiaries) of the Group established in the PRC are qualified as "High and New Technology Enterprise", respectively. In accordance with the applicable Enterprise Income Tax Law of the PRC, these subsidiaries are subject to the PRC EIT at a preferential rate of 15%.

The Company and other PRC subsidiaries are subject to the PRC EIT at a rate of 25% for the Reporting Period (30 June 2020: 25%).

由於本集團無須繳納香港利得稅的應課稅溢利，故於本報告期間並無計提香港利得稅撥備(二零二零年六月三十日：零)。

於二零二一年六月三十日，三間附屬公司(二零二零年六月三十日：兩間附屬公司)於中國成立的本集團附屬公司合資格成為「高新技術企業」。根據適用中國企業所得稅法，該等附屬公司須按15%的優惠稅率繳納中國企業所得稅。

報告期間，本公司及其他中國附屬公司須按25%的中國企業所得稅稅率納稅(二零二零年六月三十日：25%)。

9. DIVIDENDS

The directors do not propose the payment of any dividend for the Reporting Period (2020: Nil).

10. EARNINGS PER SHARE

Basic earnings per share

For the three-month and six-month periods ended 30 June 2021, the calculation of basic earnings per share has been based on the profit attributable to owners of the Company of approximately RMB3,999,000 and RMB19,647,000, respectively (three-month and six-month periods ended 30 June 2020: profit of approximately RMB8,932,000 and RMB18,250,000, respectively) and the weighted average number of 1,678,000,000 ordinary shares in issue for the three-month and six-month periods ended 30 June 2021 (2020: 1,678,000,000 ordinary shares).

Diluted earnings per share

Diluted earnings per share for the three-month and six-month periods ended 30 June 2021 and 2020 equals to basic earnings per share as there were no potential dilutive ordinary shares outstanding during these periods.

11. PROPERTY, PLANT AND EQUIPMENT

During the Reporting Period, property, plant and equipment purchased and disposed of by the Group were approximately RMB7,641,000 (30 June 2020: RMB14,444,000) and RMB1,595,000 (30 June 2020: RMB6,706,000), respectively.

In addition, during the Reporting Period, the Group has entered into lease agreements for PRC office and had recognised right-of-use assets amounted to approximately RMB443,000 (30 June 2020: Nil).

9. 股息

董事會並不建議就報告期間派付任何股息 (二零二零年：無)。

10. 每股盈利

每股基本盈利

截至二零二一年六月三十日止三個月及六個月期間，每股基本盈利乃根據本公司擁有人應佔溢利分別約人民幣3,999,000元及人民幣19,647,000元(截至二零二零年六月三十日止三個月及六個月期間：溢利分別約人民幣8,932,000元及人民幣18,250,000元)以及截至二零二一年六月三十日止三個月及六個月期間已發行普通股加權平均數1,678,000,000股(二零二零年：1,678,000,000股普通股)計算。

每股攤薄盈利

由於截至二零二一年及二零二零年六月三十日止三個月及六個月期間內並無具潛在攤薄影響的已發行普通股，因此該等期間的每股攤薄盈利與每股基本盈利相等。

11. 物業、廠房及設備

於報告期間，本集團分別購買及出售約人民幣7,641,000元(二零二零年六月三十日：人民幣14,444,000元)及人民幣1,595,000元(二零二零年六月三十日：人民幣6,706,000元)之物業、廠房及設備。

此外，於報告期間，本集團已就中國辦公室訂立租賃協議並已確認使用權資產約人民幣443,000元(二零二零年六月三十日：無)。

12. TRADE AND OTHER RECEIVABLES

12. 應收賬款及其他應收款項

		Note	At 30 June 2021 於二零二一年 六月三十日 RMB'000 人民幣千元 (Unaudited) (未經審核)	At 31 December 2020 於二零二零年 十二月三十一日 RMB'000 人民幣千元 (Audited) (經審核)
Trade receivables	應收賬款		149,188	118,343
Less: Expected credit loss ("ECL") allowance	減：預期信貸虧損(「預期信貸虧損」)撥備		(23,177)	(1,765)
			126,011	116,578
Bills receivables	應收票據	(i)	64,355	66,431
			190,366	183,009
Amounts due from fellow subsidiaries	應收同系附屬公司款項	(ii)	4,513	8,765
Amounts due from related companies	應收關連公司款項	(ii)	4,597	15,250
Amount due from the intermediate parent company	應收中間母公司款項	(ii)	79	213
Other receivables	其他應收款項	(iv)	29,188	10,854
Value-added tax recoverable	可收回增值稅	(iii)	119	164
Prepayment and deposits	預付款項及按金	(iv)	33,305	56,250
Less: ECL allowance	減：預期信貸虧損撥備		(2,133)	(4,345)
			69,668	87,151
			260,034	270,160

All of the trade and other receivables classified as current assets are expected to be recovered within one year.

預期所有分類為流動資產的應收賬款及其他應收款項可於一年內收回。

12. TRADE AND OTHER RECEIVABLES (CONTINUED)

Notes:

- (i) As at 30 June 2021, the Group had discounted bank acceptance bills of approximately RMB64,355,000 (2020: approximately RMB66,431,000). These bank acceptance bills matured within one year from date of issue. The Group considered the issuing banks of the bills are of good credit quality, therefore, the ECL of these receivables are considered as insignificant.
- (ii) The amounts are unsecured, interest-free and repayable within one year.
- (iii) Value-added tax recoverable is value-added tax paid by the Group eligible for offsetting value-added tax payable to arise on future revenue streams in accordance with relevant PRC tax laws.
- (iv) Other receivables, prepayment and deposits mainly represent deposits prepaid in advance to suppliers of approximately RMB60,360,000 (2020: approximately RMB40,674,000), which aged within one year, the management has considered the financial position of those suppliers and with closely monitoring and communication with the suppliers. The Group considered the impact on ECL to be low, therefore, the ECL of these deposits are considered as insignificant.

(a) Ageing analysis

Based on the invoice dates, which approximates the respective revenue recognition dates, the ageing analysis of the trade and bills receivables net of ECL allowance, was as follows:

		At 30 June 2021 於二零二一年 六月三十日 RMB'000 人民幣千元 (Unaudited) (未經審核)	At 31 December 2020 於二零二零年 十二月三十一日 RMB'000 人民幣千元 (Audited) (經審核)
Within 3 months	3個月內	112,784	131,241
More than 3 months but less than 12 months	超過3個月但少於12個月	71,068	50,283
Over 12 months	超過12個月	6,514	1,485
		190,366	183,009

Trade and bills receivables are due within 30-365 days (2020: 30-180 days) from the date of billing.

12. 應收賬款及其他應收款項(續)

附註：

- (i) 於二零二一年六月三十日，本集團之已貼現銀行承兌票據約為人民幣64,355,000元(二零二零年：約人民幣66,431,000元)。該等銀行承兌票據將於發行日後一年內到期。本集團認為票據的發行銀行信貸記錄良好，因此，該等應收款項的預期信貸虧損被視為屬不重大。
- (ii) 該等款項為無抵押、免息以及須於一年內償還。
- (iii) 可收回增值稅是本集團已支付的增值稅並按中國相關稅法可與日後收入所產生的應付增值稅抵銷。
- (iv) 其他應收款項、預付款項及按金主要指預付供應商的按金約人民幣60,360,000元(二零二零年：約人民幣40,674,000元)，賬齡為一年，管理層已考慮該等供應商的財務狀況，對彼等進行密切監督，並與其交流，本集團認為預期信貸虧損的影響較低，因此，預期信貸虧損的影響被視為甚微。

(a) 賬齡分析

以下為本集團之應收賬款及應收票據(扣除預期信貸虧損撥備)按發票日期(與各收入確認日期相若)呈列之賬齡分析：

應收賬款及應收票據一般在發票發出當日起計介乎30至365日內(二零二零年：30至180日)內到期支付。

12. TRADE AND OTHER RECEIVABLES (CONTINUED)

(b) Impairment of trade receivables

The movement in the ECL allowance of trade receivables is as follows:

Balance at 1 January	於一月一日的結餘
ECL recognised during the period/year	期間／年內確認之預期信貸虧損
ECL reversed during the period/year	期間／年內撥回之預期信貸虧損
Amount written off during the period/year	期間／年內撇銷金額
Acquisition of a subsidiary (note)	收購一間附屬公司(附註)
At 30 June/31 December	於六月三十日／十二月三十一日

Note:

The amount was included in the net liabilities of subsidiary acquired during the Reporting Period at the acquisition date and not include in the profit or loss of the Group during the Reporting Period.

(c) Impairment of other receivables

The movement in the ECL allowance of other receivables is as follows:

Balance at 1 January	於一月一日的結餘
ECL recognised during the period/year	期間／年內確認之預期信貸虧損
ECL reversed during the period/year	期間／年內撥回之預期信貸虧損
Amount written off during the period/year	期間／年內撇銷金額
At 30 June/31 December	於六月三十日／十二月三十一日

12. 應收賬款及其他應收款項(續)

(b) 應收賬款減值

應收賬款的預期信貸虧損撥備之變動如下：

At 30 June 2021 於二零二一年 六月三十日 RMB'000 人民幣千元 (Unaudited) (未經審核)	At 31 December 2020 於二零二零年 十二月三十一日 RMB'000 人民幣千元 (Audited) (經審核)
1,765	2,205
467	545
(640)	(678)
(491)	(307)
22,076	-
23,177	1,765

附註：

該款項計入於報告期間於收購日期收購一間附屬公司負債淨額，及不會計入報告期間本集團損益內。

(c) 其他應收款項減值

其他應收款項的預期信貸虧損撥備之變動如下：

At 30 June 2021 於二零二一年 六月三十日 RMB'000 人民幣千元 (Unaudited) (未經審核)	At 31 December 2020 於二零二零年 十二月三十一日 RMB'000 人民幣千元 (Audited) (經審核)
4,345	1,064
1,060	3,847
(139)	(509)
(3,133)	(57)
2,133	4,345

13. PRINCIPAL PROTECTED DEPOSITS

Principal protected deposits are structure deposits stated at fair value through profit or loss earning the minimum return for the range from 1.05% to 3.20% (2020: 1.30% to 3.90%) interest per annum with maturities from 28 to 45 days (2020: 35 to 167 days).

As at 30 June 2021 and 31 December 2020, all principal protected deposits have matured and no outstanding balance is noted.

14. TRADE AND OTHER PAYABLES

Included in trade and other payables are trade and bills payables, the ageing analysis of which, based on the invoice date, is as follows:

Within 3 months	3個月內
4 to 6 months	4至6個月
7 to 12 months	7至12個月
Over 1 year	1年以上
Trade and bills payables	應付賬款及應付票據
Other payables and accruals	其他應付款項及應計費用
Provisions (note)	撥備(附註)
Deferred consideration for acquisition of a subsidiary	收購一間附屬公司的遞延代價
Amounts due to fellow subsidiaries	應付同系附屬公司款項
Amount due to the immediate parent company	應付直屬母公司款項
Amount due to a non-controlling shareholder of a subsidiary	應付一間附屬公司非控股股東的款項
Amounts due to related companies	應付關連公司款項

Note:

At 31 December 2020, the balance represented the provision for estimated loss from legal proceedings in the People's Court of Fengxian District*, Shanghai (上海市奉賢區人民法院), PRC, amounted to approximately RMB5,574,000 claimed by a supplier of Fuzhou Neptunus Fuyao Pharmaceutical Company Limited ("Neptunus Fuyao"), a 80%-owned subsidiary of the Company. Neptunus Fuyao shall pay the net amount of RMB4,532,000 after deducting relevant amounts paid to the supplier.

* For identification purpose only

13. 保本型存款

保本型存款為結構性存款按公平值計入損益計量可賺取1.05%至3.20% (二零二零年: 1.30%至3.90%) 年利率利息。其到期期限由28天至45天(二零二零年: 35天至167天)。

於二零二一年六月三十日及二零二零年十二月三十一日, 所有保本型存款已屆滿及並無未償還結餘。

14. 應付賬款及其他應付款項

應付賬款及其他應付款項包括應付賬款及應付票據, 其按發票日期之賬齡分析如下:

	At 30 June 2021 於二零二一年 六月三十日 RMB'000 人民幣千元 (Unaudited) (未經審核)	At 31 December 2020 於二零二零年 十二月三十一日 RMB'000 人民幣千元 (Audited) (經審核)
Within 3 months	28,497	63,728
4 to 6 months	13,611	401
7 to 12 months	27,858	1,779
Over 1 year	30,837	1,747
Trade and bills payables	100,803	67,655
Other payables and accruals	82,508	74,197
Provisions (note)	-	5,574
Deferred consideration for acquisition of a subsidiary	10,600	-
Amounts due to fellow subsidiaries	10,671	27,349
Amount due to the immediate parent company	720	-
Amount due to a non-controlling shareholder of a subsidiary	39,044	-
Amounts due to related companies	1,886	4,734
	246,232	179,509

附註:

於二零二零年十二月三十一日, 結餘指本公司擁有80%權益的附屬公司福州海王福藥製藥有限公司(「海王福藥」)的一名供應商向中國上海市奉賢區人民法院提出申索的法律訴訟估計虧損撥備, 金額約為人民幣5,574,000元。於扣除已付予供應商的相關金額後, 海王福藥應支付淨額人民幣4,532,000元。

14. TRADE AND OTHER PAYABLES (CONTINUED)

Note: (Continued)

On 25 March 2021, Neptunus Fuyao has received a civil mediation order in relation to the legal proceedings, pursuant to which Neptunus Fuyao shall compensate loss of approximately RMB4,292,000, and pay the net amount of RMB3,250,000 (after deducting relevant amounts paid) to the supplier. Accordingly, the Group has made a reversal of provision for the claims to the supplier of approximately RMB1,282,000 during the six-month period ended 30 June 2021.

Details of the legal proceedings are disclosed in the Company's announcements dated 17 March 2020, 8 September 2020 and 7 April 2021.

15. INTEREST-BEARING BANK BORROWINGS

	Effective interest rate 實際利率	Maturity 到期年限	At 30 June 2021 於二零二一年 六月三十日 RMB'000 人民幣千元 (Unaudited) (未經審核)	At 31 December 2020 於二零二零年 十二月三十一日 RMB'000 人民幣千元 (Audited) (經審核)
Short-term bank loans				
– secured	4.35%-6.175% (2020: Nil)	Within 1 year (2020: Nil)	40,000	–
短期銀行貸款				
– 有抵押	4.35%-6.175% (二零二零年：零)	一年內 (二零二零年：零)		

Note:

The interest-bearing bank borrowings are carried at amortised cost. All of the Group's borrowings are denominated in RMB.

For the year ended 31 December 2020

At 31 December 2020, the Group has pledged buildings and prepaid lease payments included in right-of-use assets stated at an aggregate value of approximately RMB32,690,000 and RMB56,169,000 respectively. The Group has available unutilised banking facilities of RMB100,000,000.

14. 應付賬款及其他應付款項(續)

附註：(續)

於二零二一年三月二十五日，海王福藥已接獲有關法律訴訟的民事調解書，據此，海王福藥應賠償損失約人民幣4,292,000元，並向供應商支付淨額人民幣3,250,000元(經扣除相關已付款項)。因此，本集團已於截至二零二一年六月三十日止六個月向供應商撥回申索撥備約人民幣1,282,000元。

有關法律訴訟的詳情披露於本公司日期為二零二零年三月十七日、二零二零年九月八日及二零二一年四月七日的公告。

15. 附息銀行借貸

	Effective interest rate 實際利率	Maturity 到期年限	At 30 June 2021 於二零二一年 六月三十日 RMB'000 人民幣千元 (Unaudited) (未經審核)	At 31 December 2020 於二零二零年 十二月三十一日 RMB'000 人民幣千元 (Audited) (經審核)
Short-term bank loans				
– secured	4.35%-6.175% (2020: Nil)	Within 1 year (2020: Nil)	40,000	–
短期銀行貸款				
– 有抵押	4.35%-6.175% (二零二零年：零)	一年內 (二零二零年：零)		

附註：

附息銀行借貸乃按攤銷成本列賬。本集團所有借貸均以人民幣計值。

截至二零二零年十二月三十一日止年度

於二零二零年十二月三十一日，本集團的用於抵押的房屋及預付租賃款項(包括在使用權資產中)的總賬面值分別約人民幣32,690,000元及約人民幣56,169,000元。本集團擁有可供動用未動用銀行融資人民幣100,000,000元。

15. INTEREST-BEARING BANK BORROWINGS (CONTINUED)

Note: (Continued)

For the period ended 30 June 2021

At 30 June 2021, the Group has pledged buildings and prepaid lease payments included in right-of-use assets stated at an aggregate value of approximately RMB37,395,000 and RMB55,383,000 respectively. A bank borrowing was guaranteed by a director of a subsidiary up to RMB10,000,000 and pledged by a property of the director of a subsidiary. Certain bank borrowings were guaranteed by a non-controlling shareholder of a subsidiary and his related party up to RMB30,000,000 and pledged by properties of the director and his related parties. The Group has utilised banking facilities of RMB40,000,000 and available unutilised banking facilities of RMB100,000,000.

16. LEASE LIABILITIES

15. 附息銀行借貸(續)

附註：(續)

截至二零二一年六月三十日止期間

於二零二一年六月三十日，本集團的用於抵押的房屋及預付租賃款項(包括在使用權資產中)的總賬面值分別為約人民幣37,395,000元及約人民幣55,383,000元。一項銀行借貸由一間附屬公司董事提供高達人民幣10,000,000元及抵押一間附屬公司董事的物業作擔保。若干銀行借貸由一間附屬公司非控股股東及其關連方提供高達人民幣30,000,000元及董事及其關連方的物業作擔保。本集團已動用的銀行融資為人民幣40,000,000元，剩餘可供動用未動用的銀行融資為人民幣100,000,000元。

16. 租賃負債

		At 30 June 2021 於二零二一年 六月三十日 RMB'000 人民幣千元 (Unaudited) (未經審核)	At 31 December 2020 於二零二零年 十二月三十一日 RMB'000 人民幣千元 (Audited) (經審核)
Total minimum lease payments:	最低租賃款項總額：		
Due within one year	一年內到期	769	1,084
Future finance charges on leases liabilities	租賃負債的未來融資費用	(10)	(25)
Present value of leases liabilities	租賃負債現值	759	1,059
Present value of minimum lease payments:	最低租賃款項現值：		
Due within one year	一年內到期	759	1,059
Less: Portion due within one year included under current liabilities	減：計入流動負債項下一年內到期的部分	(759)	(1,059)
Portion due after one year included under non-current liabilities	計入非流動負債項下一年後到期的部分	-	-

16. LEASE LIABILITIES (CONTINUED)

During the six-months ended 30 June 2021, the total cash outflows for the leases are approximately RMB3,392,000 (year ended 31 December 2020: RMB6,366,000), of which the cash outflows amounting to RMB769,000 (year ended 31 December 2020: RMB1,537,000) are made to the intermediate parent company, Shenzhen Neptunus Group Company Limited (“Neptunus Group”), associated with lease liabilities amounting to RMB759,000 as at 30 June 2021 (year ended 31 December 2020: RMB1,059,000).

17. BUSINESS COMBINATION

On 1 June 2021, the Group completed the acquisition of 51% equity interest in Beijing Neptunus Zhongxin Pharmaceutical Co., Limited (formerly known as Beijing Zhongxin Pharmaceutical Co., Limited) (“Neptunus Zhongxin”) from three independent third parties, for a total consideration of RMB76,500,000. The acquisition has been accounted for using the purchase method.

The amount of goodwill arising as a result of the acquisition was approximately RMB90,163,000. The principal activities of Neptunus Zhongxin is manufacturing of oral solid dosage. Details of which are set out in the Group’s announcement dated 2 June 2021.

Consideration transferred

Cash	現金
Deferred consideration (note)	遞延代價(附註)

Note:

Based on the equity transfer agreement dated 22 April 2021, the deferred consideration shall be paid within the year 2021. The fair value of the deferred consideration approximates to RMB10,600,000 as at the acquisition date.

16. 租賃負債(續)

於截至二零二一年六月三十日止六個月，租賃的總現金流出約為人民幣3,392,000元(截至二零二零年十二月三十一日止年度：人民幣6,366,000元)，其中向中間母公司深圳市海王集團股份有限公司(「海王集團」)作出現金流出人民幣769,000元(截至二零二零年十二月三十一日止年度：人民幣1,537,000元)，而於二零二一年六月三十日的租賃負債達人民幣759,000元(截至二零二零年十二月三十一日止年度：人民幣1,059,000元)。

17. 業務合併

於二零二一年六月一日，本集團已完成向三名獨立第三方收購北京海王中新藥業股份有限公司(前稱為北京中新藥業股份有限公司)(「海王中新」)51%的股權，總代價為人民幣76,500,000元。該收購已使用購買法入賬。

收購產生的商譽金額約為人民幣90,163,000元。海王中新主要從事口服固體製劑的生產。有關詳情載於本集團日期為二零二一年六月二日的公告。

轉讓代價

(Unaudited)
(未經審核)
RMB'000
人民幣千元

附註：

根據日期為二零二一年四月二十二日的股權轉讓協議，遞延代價應於二零二一年內支付。遞延代價於收購日期的公平值約為人民幣10,600,000元。

17. BUSINESS COMBINATION (CONTINUED)

Consideration transferred (Continued)

The provisional fair values of the identifiable assets and liabilities of Neptunus Zhongxin as at the acquisition date were as follows:

		(Unaudited) (未經審核) RMB'000 人民幣千元
Property, plant and equipment	物業、廠房及設備	82,256
Right-of-use assets	使用權資產	30,725
Intangible assets	無形資產	29,998
Deposit for acquisition of land use rights	購買土地使用權的按金	9,817
Inventory	存貨	46,903
Trade and other receivables	應收賬款及其他應收款項	33,155
Bank balances and cash	銀行結餘及現金	2,217
Trade and other payables	應付賬款及其他應付款項	(170,605)
Contract liabilities	合約負債	(25,336)
Interest-bearing bank borrowings	付息銀行借貸	(50,000)
Tax payables	應付稅項	(75)
Deferred tax liabilities	遞延稅項負債	(15,844)
Total identifiable net liabilities at fair value	按公平值列賬之可識別負債淨值總額	<u>(26,789)</u>

17. 業務合併(續)

轉讓代價(續)

於收購日期，海王中新的可識別資產及負債公平值撥備載列如下：

17. BUSINESS COMBINATION (CONTINUED)

Goodwill arising on acquisition:

		(Unaudited) (未經審核) RMB'000 人民幣千元
Consideration transferred	已轉讓代價	76,500
Less: Non-controlling interest	減：非控股權益	(13,126)
Add: Fair value of net liabilities acquired	加：已收購負債淨值公平值	26,789
Goodwill arising on acquisition	收購產生的商譽	<u>90,163</u>
		(Unaudited) (未經審核) RMB'000 人民幣千元
Net cash outflow in respect of the above acquisition	有關上述收購的現金流出淨額	
– Bank balances and cash acquired	– 已收購銀行結餘及現金	2,217
– Cash consideration paid	– 已付現金代價	(65,900)
		<u>(63,683)</u>

Notes:

- (i) The initial accounting for the acquisition has been determined provisionally for buildings, prepaid lease payments and intangible assets to be identified and recognised separately from goodwill in relation to the respective fair values.
- (ii) The non-controlling interests were initially measured at the non-controlling interests' proportionate share of the provisional fair value of identifiable net liabilities acquired at the acquisition date.

17. 業務合併(續)

收購產生的商譽：

		(Unaudited) (未經審核) RMB'000 人民幣千元
Consideration transferred	已轉讓代價	76,500
Less: Non-controlling interest	減：非控股權益	(13,126)
Add: Fair value of net liabilities acquired	加：已收購負債淨值公平值	26,789
Goodwill arising on acquisition	收購產生的商譽	<u>90,163</u>
		(Unaudited) (未經審核) RMB'000 人民幣千元
Net cash outflow in respect of the above acquisition	有關上述收購的現金流出淨額	
– Bank balances and cash acquired	– 已收購銀行結餘及現金	2,217
– Cash consideration paid	– 已付現金代價	(65,900)
		<u>(63,683)</u>

附註：

- (i) 收購事項之初始會計處理已暫時就將識別及與商譽分開確認之樓宇、預付租賃款項及無形資產按其各自公平值予以釐定。
- (ii) 非控股權益初始按非控股權益於收購日期所收購可識別負債淨額之臨時公平值之佔比計量。

18. COMMITMENTS

- (a) Capital commitments outstanding at 30 June 2021 authorised and not provided for in the condensed consolidated interim financial statements were as follows:

		At 30 June 2021 於二零二一年 六月三十日 RMB'000 人民幣千元 (Unaudited) (未經審核)	At 31 December 2020 於二零二零年 十二月三十一日 RMB'000 人民幣千元 (Audited) (經審核)
Property, plant and equipment	物業、廠房及設備		
Contracted for, but not provided for:	已訂約但未撥備：		
Property, plant and equipment	物業、廠房及設備	969	1,759

- (b) As lessee

At 30 June 2021, the lease commitments for short-term leases are payable as follows:

		At 30 June 2021 於二零二一年 六月三十日 RMB'000 人民幣千元 (Unaudited) (未經審核)	At 31 December 2020 於二零二零年 十二月三十一日 RMB'000 人民幣千元 (Audited) (經審核)
Within 1 year	一年內	569	1,163

18. 承擔

- (a) 於二零二一年六月三十日未於簡明綜合中期財務報表獲得授權但未撥備之尚未變現資本承擔如下：

		At 30 June 2021 於二零二一年 六月三十日 RMB'000 人民幣千元 (Unaudited) (未經審核)	At 31 December 2020 於二零二零年 十二月三十一日 RMB'000 人民幣千元 (Audited) (經審核)
Property, plant and equipment	物業、廠房及設備		
Contracted for, but not provided for:	已訂約但未撥備：		
Property, plant and equipment	物業、廠房及設備	969	1,759

- (b) 作為承租人

於二零二一年六月三十日，短期租賃的租賃承擔如下：

		At 30 June 2021 於二零二一年 六月三十日 RMB'000 人民幣千元 (Unaudited) (未經審核)	At 31 December 2020 於二零二零年 十二月三十一日 RMB'000 人民幣千元 (Audited) (經審核)
Within 1 year	一年內	569	1,163

19. MATERIAL RELATED PARTY TRANSACTIONS

(a) The Group had the following significant transactions with related parties during the Reporting Period:

Name of related parties 關連方名稱	Relationship 關係	Nature of transaction 交易性質	Note 附註	For the six months ended 30 June 截至六月三十日止六個月	
				2021 二零二一年 RMB'000 人民幣千元 (Unaudited) (未經審核)	2020 二零二零年 RMB'000 人民幣千元 (Unaudited) (未經審核)
Shenzhen Neptunus Group Company Limited 深圳海王集團股份有限公司	Intermediate parent company 中間母公司	Rental of office 租用辦公室	(i)(iii)	769	816
		Services fee 服務費收入	(i)(iii)	113	-
Shenzhen Neptunus Bio-engineering Co., Ltd. ("Neptunus Bio-engineering") 深圳市海王生物工程股份有限公司 (「海王生物」)	Immediate parent company 直屬母公司	Sales of goods 銷售貨物	(ii)(iii)	30	7
Hangzhou Neptunus Bio-engineering Company Limited 杭州海王生物工程有限公司	Fellow subsidiary 同系附屬公司	Purchase of goods 購買貨物	(ii)(iii)	1,180	1,541
Zhongshan Changjian Pharmaceutical Company Limited 中山市昌健藥業有限公司	Fellow subsidiary 同系附屬公司	Sales of goods 銷售貨物	(ii)(iii)	359	167
Shenzhen Shenye Pharmaceutical Development Company Limited 深圳市深業醫藥發展有限公司	Fellow subsidiary 同系附屬公司	Sales of goods 銷售貨物	(ii)(iii)	265	175
Henan Dongsen Pharmaceutical Company Limited 河南東森醫藥有限公司	Fellow subsidiary 同系附屬公司	Sales of goods 銷售貨物	(ii)(iii)	56	177

19. 重大關連方交易

(a) 本集團於報告期間與關連方進行下列重大交易：

19. MATERIAL RELATED PARTY TRANSACTIONS (CONTINUED)

(a) The Group had the following significant transactions with related parties during the Reporting Period: (Continued)

Name of related parties 關連方名稱	Relationship 關係	Nature of transaction 交易性質	Note 附註	For the six months ended 30 June 截至六月三十日止六個月	
				2021 二零二一年 RMB'000 人民幣千元 (Unaudited) (未經審核)	2020 二零二零年 RMB'000 人民幣千元 (Unaudited) (未經審核)
Henan Neptunus Pharmaceutical Group Limited 河南海王醫藥集團有限公司	Fellow subsidiary 同系附屬公司	Sales of goods 銷售貨物	(ii)(iii)	1,937	4
Henan Enji Pharmaceutical Company Limited 河南恩濟醫藥有限公司	Fellow subsidiary 同系附屬公司	Sales of goods 銷售貨物	(ii)(iii)	309	104
Shenzhen Quanyaowang Pharmaceutical Company Limited 深圳市全藥網藥業有限公司	Fellow subsidiary 同系附屬公司	Sales of goods 銷售貨物	(ii)(iii)	3,370	3,180
		Purchases of goods 購買貨物	(ii)(iii)	–	106
		Disposal of fixed assets 處置固定資產	(iii)(vi)	–	1,177
Shandong Neptunus Yinhe Pharmaceutical Company Limited 山東海王銀河醫藥有限公司	Fellow subsidiary 同系附屬公司	Sales of goods 銷售貨物	(ii)(iii)	4,392	1,615
Jiangsu Neptunus Jiankang Bio-technology Company Limited 江蘇海王健康生物科技股份有限公司	Fellow subsidiary 同系附屬公司	Sales of goods 銷售貨物	(ii)(iii)	452	12
		Purchase of finished goods 購買製成品	(ii)(iii)	2,252	2,576

19. 重大關連方交易 (續)

(a) 本集團於報告期間與關連方進行下列重大交易：(續)

19. MATERIAL RELATED PARTY TRANSACTIONS (CONTINUED)

(a) The Group had the following significant transactions with related parties during the Reporting Period: (Continued)

Name of related parties 關連方名稱	Relationship 關係	Nature of transaction 交易性質	Note 附註	For the six months ended 30 June 截至六月三十日止六個月	
				2021 二零二一年 RMB'000 人民幣千元 (Unaudited) (未經審核)	2020 二零二零年 RMB'000 人民幣千元 (Unaudited) (未經審核)
Shenzhen Neptunus Pharmaceutical Company Limited 深圳海王藥業有限公司	Fellow subsidiary 同系附屬公司	Purchase of finished goods 購買製成品	(ii)(iii)	33,231	40,919
		Services fee 服務費收入	(ii)(iii)	-	751
		Rental expense 租賃開支	(ii)(iii)	156	156
		Purchase raw materials 購買原材料	(ii)(iii)	385	2,519
Neptunus Gongtu (Beijing) Medical Equipment Company Limited 海王共圖(北京)醫療設備有限公司	Fellow subsidiary 同系附屬公司	Sales of goods 銷售貨物	(ii)(iii)	-	1,367
Shenzhen Neptunus Medical Technology Research Institute Company Limited 深圳海王醫藥科技研究院有限公司	Fellow subsidiary 同系附屬公司	Services fee 服務費收入	(ii)(iii)	773	-
		R&D expense 研發開支	(iii)(v)	-	6,800
Guangxi Neptunus Yinhe Pharmaceutical Company Limited 廣西海王銀河醫藥有限公司	Fellow subsidiary 同系附屬公司	Sales of goods 銷售貨物	(ii)(iii)	193	-
Anyang Hengfeng Pharmaceutical Company Limited 安陽恒峰醫藥有限公司	Fellow subsidiary 同系附屬公司	Sales of goods 銷售貨物	(ii)(iii)	1,309	73

19. 重大關連方交易(續)

(a) 本集團於報告期間與關連方進行下列重大交易：(續)

19. MATERIAL RELATED PARTY TRANSACTIONS (CONTINUED)

(a) The Group had the following significant transactions with related parties during the Reporting Period: (Continued)

Name of related parties 關連方名稱	Relationship 關係	Nature of transaction 交易性質	Note 附註	For the six months ended 30 June 截至六月三十日止六個月	
				2021 二零二一年 RMB'000 人民幣千元 (Unaudited) (未經審核)	2020 二零二零年 RMB'000 人民幣千元 (Unaudited) (未經審核)
Qingdao Huaren Medical Delivery Company Limited 青島華仁醫藥配送有限公司	Fellow subsidiary 同系附屬公司	Sales of goods 銷售貨物	(ii)(iii)	–	1,970
Henan Neptunus Kangrui Pharmaceutical Company Limited 河南海王康瑞藥業有限公司	Fellow subsidiary 同系附屬公司	Sales of goods 銷售貨物	(ii)(iii)	332	538
Guangxi Guilin Neptunus Pharmaceutical Company Limited 廣西桂林海王醫藥有限公司	Fellow subsidiary 同系附屬公司	Sales of goods 銷售貨物	(ii)(iii)	720	143
Hubei Neptunus Pharmaceutical Group Company Limited 湖北海王醫藥集團有限公司	Fellow subsidiary 同系附屬公司	Sales of goods 銷售貨物	(ii)(iii)	99	211
Anhui Neptunus Guoan Pharmaceutical Company Limited 安徽海王國安醫藥有限公司	Fellow subsidiary 同系附屬公司	Sales of goods 銷售貨物	(ii)(iii)	81	237
Sulu Neptunus Pharmaceutical Group Company Limited 蘇魯海王醫藥集團有限公司	Fellow subsidiary 同系附屬公司	Sales of goods 銷售貨物	(ii)(iii)	218	667
Shenzhen Neptunus Jiankang Shiye Company Limited 深圳市海王健康實業有限公司	Fellow subsidiary 同系附屬公司	Sales of goods 銷售貨物	(ii)(iii)	–	525

19. 重大關連方交易 (續)

(a) 本集團於報告期間與關連方進行下列重大交易：(續)

19. MATERIAL RELATED PARTY TRANSACTIONS (CONTINUED)

(a) The Group had the following significant transactions with related parties during the Reporting Period: (Continued)

Name of related parties 關連方名稱	Relationship 關係	Nature of transaction 交易性質	Note 附註	For the six months ended 30 June 截至六月三十日止六個月	
				2021 二零二一年 RMB'000 人民幣千元 (Unaudited) (未經審核)	2020 二零二零年 RMB'000 人民幣千元 (Unaudited) (未經審核)
Jining Neptunus Huasen Pharmaceutical Company Limited 濟寧海王華森醫藥有限公司	Fellow subsidiary 同系附屬公司	Sales of goods 銷售貨物	(ii)(iii)	108	141
Neimenggu Neptunus Pharmaceutical Company Limited 內蒙古海王醫藥有限公司	Fellow subsidiary 同系附屬公司	Sales of goods 銷售貨物	(ii)(iii)	–	583
Zhoukou Renhe Pharmaceutical Company Limited 周口市仁和藥業有限公司	Fellow subsidiary 同系附屬公司	Sales of goods 銷售貨物	(ii)(iii)	1,147	438
Shantou Yuankang Pharmaceutical Company Limited 汕頭市元康醫藥有限公司	Fellow subsidiary 同系附屬公司	Sales of goods 銷售貨物	(ii)(iii)	–	1,835
Henan Neptunus Yinhe Pharmaceutical Company Limited 河南海王銀河醫藥有限公司	Fellow subsidiary 同系附屬公司	Sales of goods 銷售貨物	(ii)(iii)	2,026	883
Neptunus (Zhanjiang) Medical Company Limited 海王(湛江)醫藥有限公司	Fellow subsidiary 同系附屬公司	Sales of goods 銷售貨物	(ii)(iii)	166	–
Shaoyang Neptunus Pharmaceutical Company Limited 邵陽海王藥業有限公司	Fellow subsidiary 同系附屬公司	Sales of goods 銷售貨物	(ii)(iii)	178	26

19. 重大關連方交易(續)

(a) 本集團於報告期間與關連方進行下列重大交易：(續)

19. MATERIAL RELATED PARTY TRANSACTIONS (CONTINUED)

(a) The Group had the following significant transactions with related parties during the Reporting Period: (Continued)

Name of related parties 關連方名稱	Relationship 關係	Nature of transaction 交易性質	Note 附註	For the six months ended 30 June 截至六月三十日止六個月	
				2021 二零二一年 RMB'000 人民幣千元 (Unaudited) (未經審核)	2020 二零二零年 RMB'000 人民幣千元 (Unaudited) (未經審核)
Anhui Neptunus Pharmaceutical Group Company Limited 安徽海王醫藥集團有限公司	Fellow subsidiary 同系附屬公司	Sales of goods 銷售貨物	(ii)(iii)	176	–
Guangdong Neptunus Medical Group Company Limited 廣東海王醫藥集團有限公司	Fellow subsidiary 同系附屬公司	Sales of goods 銷售貨物	(ii)(iii)	166	–
Nanning Neptunus Jiangkang Bio-technology Company Limited 南寧海王健康生物科技股份有限公司	Related company 關連公司	Purchases of goods 購買貨物	(ii)(iv)	7,748	6,070
Jilin Neptunus Jiankang Bio-technology Company Limited 吉林海王健康生物科技股份有限公司	Related company 關連公司	Purchases of goods 購買貨物	(ii)(iv)	3,650	54
Jiangsu Nepstar Pharmaceutical Company Limited 江蘇海王星辰醫藥有限公司	Related company 關連公司	Sales of goods 銷售貨物	(ii)(iv)	1,703	4,825
Shenzhen Neptunus Yidianyao Pharmaceutical Company Limited (previously known as "Shenzhen Nepstar Pharmaceutical Company Limited") 深圳市海王易點藥醫藥有限公司 (前稱「深圳市海王星辰醫藥有限公司」)	Related company 關連公司	Sales of goods 銷售貨物	(ii)(iv)	1,482	14,969
Shenzhen Nepstar Health Drugstore Chain Company Limited 深圳市海王星辰健康藥房連鎖有限公司	Related company 關連公司	Sales of goods 銷售貨物	(ii)(iv)	4	1,560

19. 重大關連方交易 (續)

(a) 本集團於報告期間與關連方進行下列重大交易：(續)

19. MATERIAL RELATED PARTY TRANSACTIONS (CONTINUED)

(a) The Group had the following significant transactions with related parties during the Reporting Period: (Continued)

Name of related parties 關連方名稱	Relationship 關係	Nature of transaction 交易性質	Note 附註	For the six months ended 30 June 截至六月三十日止六個月	
				2021 二零二一年 RMB'000 人民幣千元 (Unaudited) (未經審核)	2020 二零二零年 RMB'000 人民幣千元 (Unaudited) (未經審核)
Xinjiang Neptunus Pharmaceutical Company Limited 新疆海王醫藥有限公司	Fellow subsidiary 同系附屬公司	Sales of goods 銷售貨物	(ii)(iii)	222	–
Kashi Neptunus Yinhe Pharmaceutical Company Limited 喀什海王銀河醫藥有限公司	Fellow subsidiary 同系附屬公司	Sales of goods 銷售貨物	(ii)(iii)	181	–
Shenzhen Neptunus Health Chain Store Company Limited 深圳市海王健康連鎖有限公司	Fellow subsidiary 同系附屬公司	Sales of goods 銷售貨物	(ii)(iii)	1,482	–
Shanghai Fangcheng Medical Equipment Company Limited 上海方承醫療器械有限公司	Fellow subsidiary 同系附屬公司	Sales of goods 銷售貨物	(ii)(iii)	168	–
Henan Zuojiming Pharmaceutical Company Limited 河南佐今明醫藥有限公司	Fellow subsidiary 同系附屬公司	Sales of goods 銷售貨物	(ii)(iii)	205	–

19. 重大關連方交易 (續)

(a) 本集團於報告期間與關連方進行下列重大交易：(續)

19. MATERIAL RELATED PARTY TRANSACTIONS (CONTINUED)

(a) The Group had the following significant transactions with related parties during the Reporting Period: (Continued)

Notes:

- (i) Neptunus Group leased office premises to the Group, the rental of office was charged at pre-agreed rate with reference to market prices.
- (ii) The purchases, sales, rental of storage and services fee received were transacted in the normal course of business on the same terms as those charged to and contracted with other third party suppliers and customers respectively.
- (iii) The ultimate parent company of these related parties is also the ultimate parent company of the Group.
- (iv) The director of the immediate parent company, Mr. Zhang Si Min is also the director of the ultimate parent company of the related company. The income received were transacted in the normal course of business.
- (v) The research and development expenses are for technology transfer cooperation with Neptunus Group.
- (vi) The property, plant and equipment were sold with reference to market rates.

19. 重大關連方交易(續)

(a) 本集團於報告期間與關連方進行下列重大交易：(續)

附註：

- (i) 海王集團向本集團出租辦公室物業，辦公室租金乃根據市場價格按預先同意費用收取。
- (ii) 已收到的購買、銷售、倉儲租賃費及服務費收入乃於一般業務過程中，按與其他第三方供應商及客戶所訂立的收取及訂約相同的條款進行。
- (iii) 此等關連方之最終母公司亦為本集團最終母公司。
- (iv) 直屬母公司董事張思民先生亦為關連公司最終母公司之董事。已收收入於日常業務過程中進行。
- (v) 研發費用乃用於與海王集團的技術轉讓合作。
- (vi) 物業、廠房及設備參考市價出售。

19. MATERIAL RELATED PARTY TRANSACTIONS (CONTINUED)

(b) Outstanding balances with related parties

Name of related parties 關連方名稱	Note 附註	Amounts due from related parties 關連方結欠款項		Amounts due to related parties 結欠關連方款項	
		At 30 June 2021 於二零二一年 六月三十日 RMB'000 人民幣千元 (Unaudited) (未經審核)	At 31 December 2020 於二零二零年 十二月三十一日 RMB'000 人民幣千元 (Audited) (經審核)	At 30 June 2021 於二零二一年 六月三十日 RMB'000 人民幣千元 (Unaudited) (未經審核)	At 31 December 2020 於二零二零年 十二月三十一日 RMB'000 人民幣千元 (Audited) (經審核)
Entrusted loan from the immediate parent company 直屬母公司委託借款	(i)	-	-	-	9,000
Amount due from the intermediate parent company 應收中間母公司款項		79	213	720	-
Amounts due from/to fellow subsidiaries: Shenzhen Neptunus Pharmaceutical Co., Ltd. Shandong Neptunus Yinhe Pharmaceutical Company Limited Henan Dongsen Pharmaceutical Company Limited Hangzhou Neptunus Bio-engineering Company Limited Anhui Neptunus Pharmaceutical Group Company Limited Henan Neptunus Pharmaceutical Group Company Limited Heilongjiang Province Neptunus Pharmaceutical Company Limited Sulu Neptunus Pharmaceutical Group Company Limited Shenzhen Quanyaowang Pharmaceutical Company Limited Anyang Hengfeng Pharmaceutical Company Limited	應收/應付同系附屬公司款項： 深圳海王藥業有限公司 山東海王銀河醫藥有限公司 河南東森醫藥有限公司 杭州海王生物工程股份有限公司 安徽海王醫藥集團有限公司 河南海王醫藥集團有限公司 黑龍江省海王醫藥有限公司 蘇魯海王醫藥集團有限公司 深圳市全藥網藥業有限公司 安陽恒峰醫藥有限公司	- 770 14 - 11 - 24 89 1,034 282	1,382 1,454 36 - - 320 - 377 2,562 245	2,466 7,335 - 279 5 - - - - - 4	24,286 21 - 567 44 - - - - -

19. 重大關連方交易(續)

(b) 尚未清償的關連方結餘

19. MATERIAL RELATED PARTY TRANSACTIONS (CONTINUED)

(b) Outstanding balances with related parties (Continued)

Name of related parties 關連方名稱	Note 附註	Amounts due from related parties 關連方結欠款項		Amounts due to related parties 結欠關連方款項	
		At 30 June 2021 於二零二一年 六月三十日 RMB'000 人民幣千元 (Unaudited) (未經審核)	At 31 December 2020 於二零二零年 十二月三十一日 RMB'000 人民幣千元 (Audited) (經審核)	At 30 June 2021 於二零二一年 六月三十日 RMB'000 人民幣千元 (Unaudited) (未經審核)	At 31 December 2020 於二零二零年 十二月三十一日 RMB'000 人民幣千元 (Audited) (經審核)
Shenzhen Neptunus Property Management Company Limited	深圳市海王物業管理有限公司	-	12	-	-
Henan Neptunus Yinhe Pharmaceutical Company Limited	河南海王銀河醫藥有限公司	766	686	-	557
Shenzhen Hongyang Property Management Company Limited	深圳市宏陽物業管理有限公司	30	30	-	-
Shenzhen Neptunus Medical Technology Research Institute Limited	深圳海王醫藥科技研究院有限公司	-	-	-	538
Shenzhen Neptunus Jiankang Shiye Company Limited	深圳市海王健康實業有限公司	-	205	-	-
Guangdong Neptunus Xinjian Pharmaceutical Company Limited	廣東海王新健醫藥有限公司	3	-	-	-
Xinjiang Neptunus Pharmaceutical Company Limited	新疆海王醫藥有限公司	125	125	-	-
Guangxi Guilin Neptunus Pharmaceutical Trading Company Limited	廣西桂林海王醫藥有限公司	448	209	-	-
Zhaoqing Neptunus Jiankang Bioengineering Company Limited	肇慶市海王健康生物科技有限公司	-	15	-	-
Binzhou Neptunus Huanghe Pharmaceutical Company Limited	濱州海王黃河醫藥有限公司	-	-	-	12
Shaoyang Neptunus Pharmaceutical Company Limited	邵陽海王醫藥有限公司	-	-	-	5
Puyang Neptunus Pharmaceutical Company Limited	濮陽海王醫藥有限公司	-	4	-	-
Shenzhen Shenye Pharmaceutical Development Company Limited	深圳市深業醫藥發展有限公司	-	-	-	70
Heyuan Kangchengtang Pharmaceutical Company Limited	河源市康誠堂藥業有限公司	11	25	-	-

19. 重大關連方交易(續)

(b) 尚未清償的關連方結餘(續)

19. MATERIAL RELATED PARTY TRANSACTIONS (CONTINUED)

(b) Outstanding balances with related parties (Continued)

Name of related parties 關連方名稱	Note 附註	Amounts due from related parties 關連方結欠款項		Amounts due to related parties 結欠關連方款項	
		At 30 June 2021 於二零二一年 六月三十日 RMB'000 人民幣千元 (Unaudited) (未經審核)	At 31 December 2020 於二零二零年 十二月三十一日 RMB'000 人民幣千元 (Audited) (經審核)	At 30 June 2021 於二零二一年 六月三十日 RMB'000 人民幣千元 (Unaudited) (未經審核)	At 31 December 2020 於二零二零年 十二月三十一日 RMB'000 人民幣千元 (Audited) (經審核)
Qingdao Huaren Pharmaceutical Distribution Company Limited	青島華仁醫藥配送有限公司	-	1,078	-	-
Jiangsu Neptunus Jiankang Bio-technology Co. Limited	江蘇海王健康生物科技有限 公司	48	-	535	1,249
Zhoukou Renhe Pharmaceutical Company Limited	周口市仁和藥業有限公司	263	-	-	-
Neptunus (Shaoguan) Pharmaceutical Company Limited	海王(韶關)醫藥有限公司	-	-	2	-
Neptunus (Maoming) Pharmaceutical Company Limited	海王(茂名)醫藥有限公司	-	-	11	-
Pingdingshan Neptunus Yinhe Sales Pharmaceutical Company Limited	平頂山海王銀河醫藥銷售 有限公司	-	-	6	-
Henan Enji Pharmaceutical Company Limited	河南恩濟藥業有限公司	338	-	-	-
Hubei Neptunus Pharmaceutical Group Company Limited	湖北海王醫藥集團有限公司	2	-	-	-
Henan Guanbao Yuntong Pharmaceutical Company Limited	河南冠寶雲統藥業有限公司	48	-	18	-
Henan Neptunus Huitong Pharmaceutical Company Limited	河南海王匯通醫藥有限公司	-	-	9	-
Henan Zuojinming Pharmaceutical Company Limited	河南佐今明醫藥有限公司	195	-	-	-
Shenzhen Neptunus Property Management Company Limited	深圳市海王物業管理有限公司	12	-	-	-
Kashgar Neptunus Hongkang Medical Devices Company Limited	喀什海王弘康醫療機械有限 公司	-	-	1	-
		4,513	8,765	10,671	27,349

19. 重大關連方交易(續)

(b) 尚未清償的關連方結餘(續)

Name of related parties 關連方名稱	Note 附註	Amounts due from related parties 關連方結欠款項		Amounts due to related parties 結欠關連方款項	
		At 30 June 2021 於二零二一年 六月三十日 RMB'000 人民幣千元 (Unaudited) (未經審核)	At 31 December 2020 於二零二零年 十二月三十一日 RMB'000 人民幣千元 (Audited) (經審核)	At 30 June 2021 於二零二一年 六月三十日 RMB'000 人民幣千元 (Unaudited) (未經審核)	At 31 December 2020 於二零二零年 十二月三十一日 RMB'000 人民幣千元 (Audited) (經審核)
Qingdao Huaren Pharmaceutical Distribution Company Limited	青島華仁醫藥配送有限公司	-	1,078	-	-
Jiangsu Neptunus Jiankang Bio-technology Co. Limited	江蘇海王健康生物科技有限 公司	48	-	535	1,249
Zhoukou Renhe Pharmaceutical Company Limited	周口市仁和藥業有限公司	263	-	-	-
Neptunus (Shaoguan) Pharmaceutical Company Limited	海王(韶關)醫藥有限公司	-	-	2	-
Neptunus (Maoming) Pharmaceutical Company Limited	海王(茂名)醫藥有限公司	-	-	11	-
Pingdingshan Neptunus Yinhe Sales Pharmaceutical Company Limited	平頂山海王銀河醫藥銷售 有限公司	-	-	6	-
Henan Enji Pharmaceutical Company Limited	河南恩濟藥業有限公司	338	-	-	-
Hubei Neptunus Pharmaceutical Group Company Limited	湖北海王醫藥集團有限公司	2	-	-	-
Henan Guanbao Yuntong Pharmaceutical Company Limited	河南冠寶雲統藥業有限公司	48	-	18	-
Henan Neptunus Huitong Pharmaceutical Company Limited	河南海王匯通醫藥有限公司	-	-	9	-
Henan Zuojinming Pharmaceutical Company Limited	河南佐今明醫藥有限公司	195	-	-	-
Shenzhen Neptunus Property Management Company Limited	深圳市海王物業管理有限公司	12	-	-	-
Kashgar Neptunus Hongkang Medical Devices Company Limited	喀什海王弘康醫療機械有限 公司	-	-	1	-
		4,513	8,765	10,671	27,349

19. MATERIAL RELATED PARTY TRANSACTIONS (CONTINUED)

(b) Outstanding balances with related parties (Continued)

Name of related parties 關連方名稱	Note 附註	Amounts due from related parties 關連方結欠款項		Amounts due to related parties 結欠關連方款項	
		At 30 June 2021 於二零二一年 六月三十日 RMB'000 人民幣千元 (Unaudited) (未經審核)	At 31 December 2020 於二零二零年 十二月三十一日 RMB'000 人民幣千元 (Audited) (經審核)	At 30 June 2021 於二零二一年 六月三十日 RMB'000 人民幣千元 (Unaudited) (未經審核)	At 31 December 2020 於二零二零年 十二月三十一日 RMB'000 人民幣千元 (Audited) (經審核)
Amounts due from/to related companies:	應收／應付關連公司款項：				
Shenzhen Neptunus Yidianyao Pharmaceutical Company Limited	深圳市海王易點藥醫藥有限 公司	833	6,054	-	-
Jiangsu Nepstar Pharmaceutical Company Limited	江蘇海王星辰醫藥有限公司	1,446	9,196	-	-
Jilin Neptunus Jiangkang Bio-technology Company Limited	吉林海王健康生物科技有限 公司	2,314	-	140	16
Nanning Neptunus Jiangkang Bio- technology Company	南寧海王健康生物科技有限 公司	-	-	1,644	4,718
Shenzhen Nepstar Health Drugstore Chain Company Limited	深圳海王星辰健康藥房連鎖 有限公司	4	-	-	-
Shenzhen Neptunus Daiyuanchao Bio- technology Company Limited	深圳海王大元草生物科技有限 公司	-	-	102	-
		4,597	15,250	1,886	4,734

19. 重大關連方交易 (續)

(b) 尚未清償的關連方結餘 (續)

19. MATERIAL RELATED PARTY TRANSACTIONS (CONTINUED)

(b) Outstanding balances with related parties (Continued)

Notes:

The balances with these related companies are unsecured, interest-free and repayable on demand.

- (i) On 5 April 2011, the immediate parent company further agreed to extend the repayment date of entrusted loan in the amount of RMB9,000,000 as Neptunus Bio-engineering had undertaken to the Company that it would not demand repayment of the abovementioned shareholder's entrusted loan unless and until: (1) the repayment of such shareholder's entrusted loan would not adversely affect the operations of the Company and/or its business objectives as set out in the prospectus published by the Company on 29 August 2005 (the "Prospectus"); (2) each of the independent non-executive directors was of the opinion that the repayment of such shareholder's entrusted loan would not adversely affect the operations of the Company and/or the implementation of its business objectives as set out in the Prospectus, and the Company would make an announcement in respect of the decision of the independent non-executive directors made under (2); and (3) the Company had a positive cash flow and had retained earnings in the relevant financial year ("the Repayment Conditions").

The entrusted loan is unsecured and interest-free.

During the period ended 30 June 2021, the Repayment Conditions are fully fulfilled. After the negotiation between the Company and the immediate parent company, the Company had repaid the entrusted loan to the immediate parent company on 18 February 2021.

19. 重大關連方交易(續)

(b) 尚未清償的關連方結餘(續)

附註：

與關連公司的結餘為無抵押、免息及須按要求償還。

- (i) 於二零一一年四月五日，由於海王生物向本公司承諾其將不會要求償還上述股東委託借款，直屬母公司同意進一步延後委託借款人民幣9,000,000元的償還日期，除非及直至：(1)償還該股東委託借款將不會對本公司之營運及／或本公司於二零零五年八月二十九日刊發之招股章程(「招股章程」)所載之本公司業務目標構成不利影響；(2)各獨立非執行董事認為償還該股東委託借款將不會對本公司之營運及／或實行招股章程所載之本公司業務目標構成不利影響，以及本公司將就獨立非執行董事根據(2)所作決定作出公告；及(3)本公司於有關財政年度錄得正數現金流量及保留盈利(「還款條件」)。

委託借款乃無抵押及免息。

於截至二零二一年六月三十日止期間，還款條件已全部達成。經本公司與直屬母公司協商，本公司已於二零二一年二月十八日向直屬母公司償還委託借款。

19. MATERIAL RELATED PARTY TRANSACTIONS (CONTINUED)

(b) Outstanding balances with related parties (Continued)

Note: (Continued)

- (ii) Reconciliation of the Group's amounts due from/to related parties arising from the ordinary course of business which are trade in nature and non-trade nature, considered of the following:

19. 重大關連方交易(續)

(b) 尚未清償的關連方結餘(續)

附註：(續)

- (ii) 本集團於業務日常過程產生，為貿易性質及非貿易性質之應收／應付關連方款項對賬包括下列各項：

		Amounts due from related parties 關連方結欠款項		Amounts due to related parties 結欠關連方款項	
		At 30 June 2021 於二零二一年 六月三十日 RMB'000 人民幣千元 (Unaudited) (未經審核)	At 31 December 2020 於二零二零年 十二月三十一日 RMB'000 人民幣千元 (Audited) (經審核)	At 30 June 2021 於二零二一年 六月三十日 RMB'000 人民幣千元 (Unaudited) (未經審核)	At 31 December 2020 於二零二零年 十二月三十一日 RMB'000 人民幣千元 (Audited) (經審核)
Trade nature	貿易性質				
Amounts due from/to fellow subsidiaries	應收／應付同系附屬公司款項	4,513	8,723	10,671	27,349
Amounts due from/to related companies	應收／應付關連公司款項	4,597	15,250	1,886	4,734
		9,110	23,973	12,557	32,083
Non-trade nature	非貿易性質				
Entrusted loan from the immediate parent company	直屬母公司委託借款	-	-	-	9,000
Amount due from the intermediate parent company	應付直屬母公司款項	79	213	720	-
Amounts due from/to fellow subsidiaries	應收／應付同系附屬公司款項	-	42	-	-
Amounts due to a non-controlling shareholder of a subsidiary	應付附屬公司非控股股東款項	-	-	39,044	-
		79	255	39,764	9,000
		9,189	24,228	52,321	41,083

19. MATERIAL RELATED PARTY TRANSACTIONS (CONTINUED)

(b) Outstanding balances with related parties (Continued)

Note: (Continued)

- (a) The ageing analysis of amounts due from related parties arising from the ordinary course of business which are trade in nature and based on invoice date is as follows:

		At 30 June 2021 於二零二一年 六月三十日 RMB'000 人民幣千元 (Unaudited) (未經審核)	At 31 December 2020 於二零二零年 十二月三十一日 RMB'000 人民幣千元 (Audited) (經審核)
Within 3 months	3個月內	8,055	14,846
More than 3 months but less than 12 months	超過3個月但少於12個月	1,025	9,039
Over 12 months	超過12個月	30	88
		9,110	23,973

- (b) The ageing analysis of amounts due to related parties arising from the ordinary course of business which are trade in nature and based on invoice date is as follows:

		At 30 June 2021 於二零二一年 六月三十日 RMB'000 人民幣千元 (Unaudited) (未經審核)	At 31 December 2020 於二零二零年 十二月三十一日 RMB'000 人民幣千元 (Audited) (經審核)
Within 3 months	3個月內	12,169	31,694
More than 3 months but less than 12 months	超過3個月但少於12個月	311	-
Over 12 months	超過12個月	77	389
		12,557	32,083

19. 重大關連方交易(續)

(b) 尚未清償的關連方結餘(續)

附註：(續)

- (a) 於日常業務過程中產生屬貿易性質及基於發票日期的應收關連方款項賬齡分析如下：

		At 30 June 2021 於二零二一年 六月三十日 RMB'000 人民幣千元 (Unaudited) (未經審核)	At 31 December 2020 於二零二零年 十二月三十一日 RMB'000 人民幣千元 (Audited) (經審核)
Within 3 months	3個月內	8,055	14,846
More than 3 months but less than 12 months	超過3個月但少於12個月	1,025	9,039
Over 12 months	超過12個月	30	88
		9,110	23,973

- (b) 於日常業務過程中產生屬貿易性質及基於發票日期的應付關連方款項賬齡分析如下：

		At 30 June 2021 於二零二一年 六月三十日 RMB'000 人民幣千元 (Unaudited) (未經審核)	At 31 December 2020 於二零二零年 十二月三十一日 RMB'000 人民幣千元 (Audited) (經審核)
Within 3 months	3個月內	12,169	31,694
More than 3 months but less than 12 months	超過3個月但少於12個月	311	-
Over 12 months	超過12個月	77	389
		12,557	32,083

MANAGEMENT DISCUSSION AND ANALYSIS

BUSINESS REVIEW

During the Reporting Period, the Group was principally engaged in the research and development, manufacturing and selling of medicines, and the purchase and sales of medicines and healthcare food products in the PRC. The medicines being sold by the Group mainly cover several therapeutic areas which are oncology, cardiovascular system, respiratory system, digestive system and mental disorders.

RESEARCH AND DEVELOPMENT, MANUFACTURING AND SELLING OF MEDICINES

Currently, the Group has two pharmaceutical production bases, which are respectively located in Jin'an District, Fuzhou, Fujian Province, the PRC ("Fuzhou Production Base") and Miyun Economic Development Zone, Beijing City, the PRC ("Beijing Production Base"). Fuzhou Production Base possesses Chinese medicines (including more than a dozen of dosage forms such as tablets, capsules, granules, oral solutions and tinctures) and chemical medicines (which include various dosage forms namely tablets, capsules, granules, small volume injections and large volume injections), with nearly 500 approval documents of Guoyaozhunzi being registered, of which, approximately 170 varieties have been included into the "Catalogue of Drugs for Basic National Medical Insurance" (國家基本醫療保險藥品目錄). The Fuzhou Production Base is the only narcotic production base in Fujian Province designated by the State. The Beijing Production Base is under Neptunus Zhongxin, a subsidiary acquired by the Group during the Reporting Period. It mainly produces chemical medicines (including tablets, hard capsules and powders) and has approximately 140 approval documents of Guoyaozhunzi, of which approximately 90 products are included into the "Catalogue of Drugs for Basic National Medical Insurance" (國家基本醫療保險藥品目錄) and approximately 60 products are included into the "National Essential Drug List" (國家基本藥物目錄).

管理層討論及分析

業務回顧

本集團於報告期間主要在中國從事藥品的研發、生產及銷售，以及藥品及保健食品的購銷。本集團銷售的藥品主要涵蓋腫瘤、心血管系統、呼吸系統、消化系統、精神障礙等多個治療領域。

藥品研發、生產及銷售

目前，本集團擁有兩個藥品生產基地，分別位於中國福建省福州市晉安區（「福州生產基地」）及中國北京市密雲經濟開發區（「北京生產基地」）。福州生產基地擁有中成藥（含片劑、膠囊劑、顆粒劑、口服液、酏劑等十幾個劑型）、化藥（含片劑、膠囊劑、顆粒劑、小容量注射劑、大容量注射劑等多個劑型）等近500個國藥准字批准文號，其中約有170個品規入選了國家基本醫療保險藥品目錄。福州生產基地，是國家在福建省唯一指定的麻醉品生產基地。北京生產基地隸屬於本集團於報告期間收購之附屬公司海王中新，其主要生產化藥（含片劑、硬膠囊劑、散劑），持有約140個國藥准字批准文號，其中約有90個品規入選國家基本醫療保險藥品目錄，約有60個品規入選了國家基本藥物目錄。

BUSINESS REVIEW (Continued)

RESEARCH AND DEVELOPMENT, MANUFACTURING AND SELLING OF MEDICINES (Continued)

The Group mainly fulfills the internal development demands through conducting independent research and development and cooperation with external research and development institutions. Two pharmaceutical manufacturing subsidiaries of the Group are recognized as high-tech enterprises in Fujian Province and another pharmaceutical manufacturing subsidiary is recognized as national high-tech enterprises and all of which are entitled to enjoy preferential corporate income tax treatment for high-tech enterprises. The said three subsidiaries currently possess various new drugs and exclusive products with self-owned intellectual property rights, including Tegafur, Gimeracil and Oteracil Potassium Tablets (the "TGOP Tablets" or 替吉奧片, a drug for anti-gastric cancer), Xiaozheng Yigan Tablets (消症益肝片, an anti-liver-cancer drug), Proteoglycan Tablets (多糖蛋白片, for enhancing the immune system), Biyuan Capsules (鼻淵膠囊, an anti-rhinitis medicine), Amaranth Berberine Capsules (萹草黃連素膠囊, a drug for acute diarrhea), Disodium glycyrrhizinate (甘草酸二鈉, a drug for anti-inflammatory and liver protection), Spironolactone Tablets (螺內酯片, a drug for auxiliary diuresis), Ligustrazine Phosphate Tablets (磷酸川芎嗪片, a drug for ischemic cerebrovascular disease), Pre-filled Catheter Flusher (預充式導管沖洗器, a Class III medical device) and HTK Myocardial Protection Cardioplegic Solution (HTK 心肌保護停跳液, a Class III medical device). During the Reporting Period, the Group's two new drug products were approved for registration and passed the drug GMP compliance inspection before its launch.

Under the national policy in relation to quality consistency evaluation for generic drugs, appropriate types of medicines were proactively selected by a pharmaceutical manufacturing subsidiary of the Group and such medicines were selected to undergo the quality consistency evaluation for generic drugs. Currently, four of the selected medicines of the Group, Sodium Bicarbonate Tablets, Norfloxacin Capsules, Propranolol Hydrochloride Tablets and Metformin Hydrochloride Tablets, have already passed the consistency evaluation. The relevant work of quality consistency evaluation for other selected medicines is under orderly progress.

業務回顧(續)

藥品研發、生產及銷售(續)

本集團主要通過自主研發和與外部研發機構合作的方式滿足內部研發需求。本集團旗下現有兩家製藥附屬公司為福建省高新技術企業，另有一家製藥附屬公司為國家高新技術企業，均可享受高新技術企業所得稅優惠政策。上述三家附屬公司目前擁有多個新藥和自主知識產權獨家產品，如抗胃癌藥替吉奧片(「替吉奧片」)、抗肝癌藥消症益肝片、提高免疫力的多糖蛋白片、抗鼻炎用藥鼻淵膠囊、急性腹瀉用藥萹草黃連素膠囊、抗炎保肝用藥甘草酸二鈉、輔助性利尿藥螺內酯片、缺血性腦血管疾病用藥磷酸川芎嗪片、預充式導管沖洗器(國家第三類醫療器械產品)以及HTK心肌保護停跳液(國家第三類醫療器械產品)等。於報告期間，本集團有兩個新藥產品的註冊申報獲得批准並通過了上市前藥品GMP符合性檢查。

根據有關仿製藥一致性評價的政策，本集團旗下相關製藥附屬公司積極篩選品種並啟動了仿製藥一致性評價工作。目前，本集團有四個品種，即碳酸氫鈉片、諾氟沙星膠囊、鹽酸普萘洛爾片及鹽酸二甲雙胍片，已成功通過一致性評價。其他品種的一致性評價相關工作正在有序推進中。

BUSINESS REVIEW (Continued)

RESEARCH AND DEVELOPMENT, MANUFACTURING AND SELLING OF MEDICINES (CONTINUED)

Affected by the national policies and the fluctuation of the market, the prices of the pharmaceutical products are decreasing with prices of active ingredients increasing; in the meantime, the regulation and inspection on drug production and quality has become more stringent and the competition of bidding for drugs has become more intensified. All these have imposed continuous pressure on the relevant pharmaceutical manufacturing subsidiaries of the Company. Meanwhile, the centralized procurement of drugs organized by the State has entered the stage of regular operation and the landscape of the medical industry is changing at an accelerating pace. To mitigate the above adverse impact, the Group paid close attention to the trend of the policies and the market, actively leveraged on the opportunities brought by the changing industry, increased investment in the research and development and the product quality assurance system and expanded the existing sales networks, so as to ensure the sustainable and healthy development of the Group's pharmaceutical manufacturing and sales business. During the Reporting Period, the price of certain products of the Group decreased, resulting in a decrease in sales revenue. However, the sales of anti-tussive medicines rebounded as compared to last year, and the promotion of key products has started to yield results. Therefore, overall, the business of the pharmaceutical production and sales segment of the Group developed steadily with slight growth.

PURCHASE AND SALES OF MEDICINES AND HEALTHCARE FOOD PRODUCTS

Currently, the main products distributed by the Group are medicines and healthcare food products, which include the well-known product series of the Neptunus Ginkgo Leaves Tablets (海王銀杏葉片) and Neptunus Jinzun (海王金樽). Such products are mainly distributed to the end medical institutions through professional sales promotion companies and to the end users through large and medium-sized chain pharmacies.

During the Reporting Period, the purchase and sales of medicines and healthcare food products segment of the Group reduced the distribution of several prescription products. In addition, the sales were affected to a certain extent by the decline in the overall growth rate of the pharmaceutical retail industry of the OTC market, the impact of the national drug procurement and the impact of "Internet + Medicine". Therefore, the revenue of this segment declined during the Reporting Period.

業務回顧(續)

藥品研發、生產及銷售(續)

受國家政策及市場波動影響，藥品降價、原料藥漲價、藥品生產及質量檢查趨嚴、藥品投標競爭加劇，本公司相關製藥附屬公司經營壓力持續加大。同時，國家組織藥品集中採購已進入常態化運行階段，醫藥格局正在加快變化。為消除上述不利影響，本集團密切關注國家政策及市場動向，積極把握行業變化帶來的機遇，加大研發及質量體系的投入，並拓展現有的銷售網絡，確保本集團藥品生產及銷售業務的穩健發展。於報告期間，本集團部分產品價格下降，導致銷售收入下降，但止咳類產品之銷售較去年有所回暖，且重點產品之推廣初見成效，因此，整體而言，本集團藥品生產及銷售分部之業務穩健發展，且略有增長。

藥品及保健食品購銷

目前，本集團主要代理產品為藥品及保健食品，其中包括著名的海王銀杏葉片系列產品和海王金樽系列產品。代理產品主要通過專業銷售推廣公司分銷至終端醫療機構以及通過大中型連鎖藥店銷售給終端客戶。

於報告期間，本集團藥品及保健食品購銷分部減少了部分處方產品之代理。此外，非處方藥市場受醫藥零售行業整體增速下行、國家藥品集採傳導影響以及「互聯網+醫藥」的衝擊，銷售受到一定影響。因此，該分部於報告期間之收入有所下降。

BUSINESS REVIEW (Continued)

PURCHASE AND SALES OF MEDICINES AND HEALTHCARE FOOD PRODUCTS (CONTINUED)

In order to stabilize its business and maintain growth, the purchase and sales segment of the Group's medicines and healthcare food products continues to expand its product line by proactively adopting a diversified development strategy, increasing efforts in regional market development, keeping up with market trends, launching a series of promotional activities, conference, team training, and introducing Neptunus Zhongxin's products and market demand products.

FINANCIAL REVIEW

The Group's revenue during the Reporting Period was approximately RMB391,194,000, representing a decrease of 14.87% from approximately RMB459,546,000 for the corresponding period of last year. In relation to the Group's revenue, approximately RMB233,766,000, which amounted to approximately 59.76% of the Group's total revenue, was derived from the manufacturing and selling of medicines segment, while approximately RMB157,428,000, which amounted to approximately 40.24% of the Group's total revenue, was derived from the sales and distribution of medicines and healthcare products segment. During the Reporting Period, the revenue from the manufacturing and selling of medicines segment increased by approximately 17.19% as compared with the corresponding period of last year, while the revenue from the sales and distribution of medicines and healthcare products segment decreased by approximately 39.47% as compared with the corresponding period of last year. Therefore the overall revenue of the Group decreased.

During the Reporting Period, the Group's gross profit margin was approximately 47%, representing a decrease of approximately 5% from approximately 52% for the corresponding period of last year. The decrease in gross profit margin was mainly attributable to reasons such as the adjustment of freight charges as cost of sales of principal business according to the new revenue standards and the reduction in number of products with high gross profit margin sold as agent.

The Group's gross profit during the Reporting Period was approximately RMB185,303,000, representing a decrease of approximately 22.73% from approximately RMB239,800,000 for the corresponding period of last year. The decrease was mainly attributed to the decrease in the Group's total revenue and the gross profit margin has decreased as a result.

During the Reporting Period, the Group's selling and distribution expenses were approximately RMB121,177,000, representing a decrease of approximately 28.14% from approximately RMB168,634,000 for the corresponding period of last year. The decrease in selling and distribution expenses was mainly due to the decrease of revenue, the adjustment of freight charges as cost of sales of principal business according to the New Revenue Standards and the adjustment of varieties and structure of products sold as agent.

業務回顧(續)

藥品及保健食品購銷(續)

為穩定業務、保持增長，本集團藥品及保健食品購銷分部積極採取多元化發展戰略、加大區域市場開發力度、緊跟市場熱點，開展一系列促銷活動、啟動會、團隊融訓、引進海王中新產品及市場需求產品，不斷拓寬產品線。

財務回顧

本集團於報告期間之收入約為人民幣391,194,000元，較去年同期約人民幣459,546,000元下降約14.87%。於本集團收入中，約人民幣233,766,000元來自於生產和銷售藥品分部，佔本集團總收入約59.76%；約人民幣157,428,000元來自於銷售及分銷藥品及保健品分部，佔本集團總收入約40.24%。於報告期間，生產和銷售藥品分部的收入較去年同期上升約17.19%；銷售及分銷藥品及保健品分部的收入較去年同期下降約39.47%，因此本集團整體收入有所下降。

本集團於報告期間之毛利率約為47%，較去年同期約52%下降約5%。毛利率較去年下降主要是因為採用新收入準則，運費調整計入主營業務成本，及減少代理高毛利率品種等因素。

本集團於報告期間之毛利約為人民幣185,303,000元，較去年同期約人民幣239,800,000元下降約22.73%。毛利的下降主要是因為本集團整體收入有所下降，且毛利率也有所下降。

本集團於報告期間之銷售及分銷開支約為人民幣121,177,000元，較去年同期約人民幣168,634,000元下降約28.14%。銷售及分銷開支減少主要是由於隨收入的減少，銷售及分銷開支相應減少且根據新收入準則，運費調整計入主營業務成本，及代理產品的類型結構調整。

FINANCIAL REVIEW (Continued)

The Group's administrative expenses for the Reporting Period were approximately RMB34,465,000, representing an increase of approximately 16.05% from approximately RMB29,699,000 for the corresponding period of last year. The increase was mainly due to the expiry of the periodical deduction and exemption of social insurance premium measures during the pandemic and the increase in administrative expenses resulted from the acquisition of Neptunus Zhongxin.

During the Reporting Period, the Group's other operating expenses amounted to approximately RMB17,230,000, representing a decrease of approximately 38.50% from approximately RMB28,015,000 for the corresponding period of last year. The decrease was mainly because the intangible assets had no impairment loss during the Reporting Period, whereas there was a provision for impairment loss of approximately RMB13,588,000 for the corresponding period of last year.

The Group's finance costs for the Reporting Period amounted to approximately RMB738,000, representing an increase of approximately 44.71% from approximately RMB510,000 for the corresponding period of last year. The increase in finance costs was mainly due to the interest expenses newly incurred from Neptunus Zhongxin's banking loans.

For the reasons above, the Group's profit after tax increased from approximately RMB19,254,000 for the corresponding period of last year to approximately RMB22,685,000 for the Reporting Period, representing an increase of approximately 17.82%. Profit attributable to the owners of the Company increased from approximately RMB18,250,000 for the corresponding period of last year to approximately RMB19,647,000 for the Reporting Period, representing an increase of approximately 7.65%.

LIQUIDITY AND FINANCIAL RESOURCES

The Group usually finances its operating and investing activities with its internal financial resources and bank loans. The Group's transactions are mainly denominated in Renminbi and the Group reviews its demand for working capital and financing on a regular basis.

BANKING FACILITIES

As at 30 June 2021, Neptunus Fuyao has pledged buildings and prepaid lease payments to secure a banking facility of RMB100,000,000, which has not been utilized yet. Neptunus Zhongxin has pledged private properties of a director and personal guarantee provided by a director and his related parties to secure banking facilities of RMB40,000,000, which have been fully utilized. Therefore, the Group has a short-term banking borrowing of RMB40,000,000 which remains outstanding.

財務回顧(續)

本集團於報告期間之行政開支約為人民幣34,465,000元，較去年同期約人民幣29,699,000元上升約16.05%。行政開支增加主要是由於疫情期間階段性減免社會保險費政策已停止執行，及收購海王中新導致行政開支有所增加。

本集團於報告期間之其他經營開支約為人民幣17,230,000元，較去年同期約人民幣28,015,000元下降約38.50%。其他經營開支減少主要是由於報告期間無形資產未發生減值，去年同期計提了無形資產減值撥備人民幣13,588,000元。

本集團於報告期間之財務成本約為人民幣738,000元，較去年同期約人民幣510,000元上升約44.71%。財務成本增加的主要原因為新增海王中新銀行借款利息支出。

由於上述原因，本集團於報告期間之稅後溢利約為人民幣22,685,000元，較去年同期約人民幣19,254,000元上升約17.82%；本公司於報告期間之擁有人應佔溢利約為人民幣19,647,000元，較去年同期約人民幣18,250,000元上升約7.65%。

流動資金及財務資源

本集團一般以內部財務資源及銀行借貸作為其經營及投資活動之資金。本集團之買賣交易主要以人民幣列值，並定期檢討對流動資金及融資的需要。

銀行融資

於二零二一年六月三十日，海王福藥以房屋及預付租賃款項作抵押，銀行融資額度為人民幣100,000,000元，該銀行融資額度尚未動用。海王中新以一位董事之私人房產以及一位董事及其關連方之個人擔保作抵押，取得銀行融資額度人民幣40,000,000元，該銀行融資額度已全部動用。因此本集團有短期銀行借款人民幣40,000,000元尚未歸還。

LIQUIDITY AND FINANCIAL RESOURCES (Continued)

SHAREHOLDER'S ENTRUSTED LOAN

The Company obtained a shareholder's entrusted loan of RMB9,000,000 from Shenzhen Neptunus Bio-engineering Co., Ltd. ("Neptunus Bio-engineering") through an entrusted arrangement with a bank. Neptunus Bio-engineering had undertaken to the Company that it would not demand repayment of the above-mentioned shareholder's entrusted loan unless and until: (1) the repayment of such shareholder's entrusted loan would not adversely affect the operations of the Company and/or its business objectives as set out in the prospectus published by the Company on 29 August 2005 (the "Prospectus"); (2) each of the independent non-executive Directors was of the opinion that the repayment of such shareholder's entrusted loan would not adversely affect the operations of the Company and/or the implementation of its business objectives as set out in the Prospectus, and the Company would make an announcement in respect of the decision of the independent non-executive Directors made under (2); and (3) the Company had positive cash flow and retained earnings in the relevant financial year (the "Repayment Conditions").

As the above-mentioned Repayment Conditions were fully satisfied, after the negotiation between the Company and Neptunus Bio-engineering, the Company has repaid the above-mentioned shareholder's entrusted loan to Neptunus Bio-engineering on 18 February 2021.

PLEDGE OF ASSETS

As at 30 June 2021, the available banking facilities of RMB100,000,000 of the Group were secured by pledge of its buildings and prepaid lease payments and the pledged buildings and prepaid lease payments were stated at an aggregate value of approximately RMB92,778,000.

FOREIGN CURRENCY RISK

During the Reporting Period, the Group's operating revenue, major selling costs and capital expenditure were denominated in RMB. As at 30 June 2021, the Group's cash and cash equivalents were mainly denominated in RMB. As such, the foreign currency risk facing the Group is limited. Currently, the Group has not adopted any financial instrument for hedging purposes.

GEARING RATIO

As at 30 June 2021, the gearing ratio of the Group, calculated by dividing the total borrowings by total equity and multiplied by 100%, was approximately 4.42% (31 December 2020: nil).

流動資金及財務資源(續)

股東委託借款

本公司透過與銀行訂立委託安排自深圳市海王生物工程股份有限公司(「海王生物」)取得股東委託借款人民幣9,000,000元。海王生物已向本公司承諾將不會要求本公司償還上述股東委託借款，除非及直至：(1)償還該股東委託借款將不會對本公司之業務及／或本公司於二零零五年八月二十九日刊發之招股章程(「招股章程」)所載本公司之業務目標構成不利影響；(2)各獨立非執行董事認為償還該股東委託借款將不會對本公司之業務及／或實行招股章程所載本公司之業務目標構成不利影響，以及本公司將就獨立非執行董事根據(2)所作決定作出公告；及(3)本公司於有關財政年度取得正數現金流量及保留盈利(「還款條件」)。

由於上述還款條件均已達成，經本公司與海王生物協商，本公司已於二零二一年二月十八日向海王生物償還委託借款。

資產抵押

於二零二一年六月三十日，本集團可動用之銀行融資為人民幣100,000,000元，以其房屋及預付租賃款項作抵押，且已抵押房屋及預付租賃款項的賬面值合計約人民幣92,778,000元。

匯率風險

於報告期間，本集團之經營收入、主要銷售成本及資本開支均以人民幣列值。於二零二一年六月三十日，本集團現金及現金等價物主要以人民幣列值，因此，本集團面臨的匯率風險不大。目前本集團並無採用任何金融工具作對沖用途。

資產負債率

於二零二一年六月三十日，本集團資產負債率(以總借款除以總權益乘以100%計算)約為4.42%(二零二零年十二月三十一日：無)。

SIGNIFICANT INVESTMENT HELD

Save as disclosed in this report, there was no other significant investment held by the Company during the Reporting Period.

CAPITAL STRUCTURE

During the Reporting Period, there has been no change in the capital structure of the Company. The capital of the Company comprises its shares and other reserves.

INTERIM DIVIDEND

The Board did not recommend the payment of any interim dividend for the Reporting Period (2020: Nil).

MATERIAL ACQUISITIONS AND DISPOSALS OF SUBSIDIARIES, ASSOCIATES AND JOINT VENTURES

The Group had not made any material acquisitions and disposals of subsidiaries, associates, and joint ventures during the Reporting Period.

CONTINGENT LIABILITY

As at 30 June 2021, the Group had no significant contingent liabilities.

FUTURE PLANS FOR MATERIAL INVESTMENTS AND CAPITAL ASSETS

As at 30 June 2021, the Group did not have concrete plans for material investments and capital assets.

EMPLOYEES AND REMUNERATION POLICY

As at 30 June 2021, the Group employed a total of 1,314 employees.

During the Reporting Period, the staff costs including directors' remuneration which amounted to approximately RMB59,077,000. Employees are remunerated according to their performance and work experience. The Group raised the salaries and improved fringe benefits for its employees to maintain competitiveness and broaden appeal of the Group. The employees' incentives were reviewed and determined annually pursuant to the remuneration, bonus policies and/or share options of the Group based on the performance of the employees. The Group also provided various other benefits to its employees.

The Group monitored closely the remuneration and fringe benefits of the employees and rewarded employees in accordance with the Group's business performance. In addition, training and development opportunities for the employees were also provided by the Group.

所持有的重大投資

除本報告披露者外，於報告期間，本公司並無持有任何其他重大投資。

資本結構

於報告期間，本公司的資本結構並沒有改動。本公司資本包括其股份及其他儲備。

中期股息

董事會並不建議就報告期間派付任何股息(二零二零年：無)。

附屬公司、聯營公司及合營公司的重大收購及出售

於報告期間，本集團並無收購或出售附屬公司、聯營公司及合營公司之事項。

或然負債

於二零二一年六月三十日，本集團並無任何重大或然負債。

重大投資及資本資產的未來計劃

於二零二一年六月三十日，本集團未有針對重大投資及資本資產的具體計劃。

僱員及薪酬政策

於二零二一年六月三十日，本集團僱用合共1,314名員工。

於報告期間，僱員成本(包括董事酬金)約為人民幣59,077,000元。僱員薪金根據其表現及工作經驗釐定。本集團調增僱員之薪金及福利以維持企業競爭力及增加企業吸引力，而僱員之獎勵乃根據本集團之薪酬及獎金及或購股權政策按僱員表現每年檢討及釐定。本集團為僱員提供多種福利。

本集團密切監控僱員之薪金及福利，並根據本集團之業績表現獎勵僱員。此外，本集團亦為僱員提供培訓及發展機會。

CAPITAL COMMITMENTS

As at 30 June 2021, the Group had contracted commitments for future capital expenditure of approximately RMB969,000.

INTERESTS AND SHORT POSITIONS OF DIRECTORS, SUPERVISORS AND CHIEF EXECUTIVE IN THE LISTED SECURITIES

As far as the Directors and supervisors of the Company are aware, as at 30 June 2021, the interests and short positions of the Directors, supervisors and chief executive of the Company in the shares, underlying shares and debentures of the Company and its associated corporations (within the meaning of Part XV of the Securities and Futures Ordinance (the "SFO")) which were required to be notified to the Company and the Stock Exchange pursuant to Part XV of the SFO (including interests or short positions which they were taken or deemed to have under such provisions of the SFO), or were required, pursuant to section 352 of the SFO, to be and were recorded in the register to be kept by the Company, or were required, pursuant to Rule 5.46 to Rule 5.67 of the GEM Listing Rules to be notified to the Company and the Stock Exchange were as follows:

Long positions in shares of associated corporations of the Company:

Director/Supervisor	Capacity	Type of interests	Name of associated corporation	Number of shares held in associated corporation	Approximate percentage of the associated corporation's issued share capital
董事／監事	身份	權益種類	相聯法團名稱	持有相聯法團之股份數目	佔相聯法團之已發行股本概約百分比
Mr. Zhang Feng (Note (a)) 張鋒先生(附註(a))	Beneficial owner 實益擁有人	Personal 個人	Neptunus Bio-engineering 海王生物	1,331,093	0.05%
Ms. Yu Lin (Note (b)) 于琳女士(附註(b))	Beneficial owner 實益擁有人	Personal 個人	Neptunus Bio-engineering 海王生物	900,000	0.03%
Mr. Shen Da Kai (Note (c)) 沈大凱先生(附註(c))	Beneficial owner 實益擁有人	Personal 個人	Neptunus Bio-engineering 海王生物	2,000,000	0.07%
Ms. Cao Yang (Note (d)) 曹陽女士(附註(d))	Beneficial Owner 實益擁有人	Personal 個人	Neptunus Bio-engineering 海王生物	200,000	0.01%

資本承諾

於二零二一年六月三十日，本集團有未來資本支出之合約承擔約人民幣969,000元。

董事、監事及最高行政人員於上市證券中的權益及淡倉

就本公司董事及監事所知，於二零二一年六月三十日，本公司董事、監事及最高行政人員於本公司及其相聯法團(定義見證券及期貨條例(「證券及期貨條例」)第十五部)之股份、相關股份及債權證中擁有須根據證券及期貨條例第十五部知會本公司及聯交所之權益及淡倉(包括根據證券及期貨條例之有關條文被當作或視為彼等擁有之權益或淡倉)，或須根據證券及期貨條例第352條須由本公司存備之登記冊將記錄及已記錄之權益及淡倉，或根據GEM上市規則第5.46條至5.67條之規定而須知會本公司及聯交所之權益及淡倉如下：

於本公司相聯法團股份之好倉：

Notes:

- (a) Mr. Zhang Feng, chairman of the Board and deputy chairman and non-independent director of the 8th session of the board of directors and president of Neptunus Bio-engineering, was beneficially interested in approximately 0.05% of the entire issued share capital of Neptunus Bio-engineering, the Company's controlling shareholder, which in turn held directly and indirectly the beneficial interest in approximately 73.51% of the entire issued share capital of the Company, of which 70.38% was directly held and 3.13% was indirectly held through Shenzhen Neptunus Oriental Investment Company Limited ("Neptunus Oriental").
- (b) Ms. Yu Lin, non-executive Director, was beneficially interested in approximately 0.03% of the entire issued share capital of Neptunus Bio-engineering, the Company's controlling shareholder, which in turn held directly and indirectly the beneficial interest in approximately 73.51% of the entire issued share capital of the Company, of which 70.38% was directly held and 3.13% was indirectly held through Neptunus Oriental.
- (c) Mr. Shen Da Kai, non-executive Director, was beneficially interested in approximately 0.07% of the entire issued share capital of Neptunus Bio-engineering, the Company's controlling shareholder, which in turn held directly and indirectly the beneficial interest in approximately 73.51% of the entire issued share capital of the Company, of which 70.38% was directly held and 3.13% was indirectly held through Neptunus Oriental.
- (d) Ms. Cao Yang, employee representative supervisor and human resources director of the Company and vice general manager, supervisor and head of human resources of Neptunus Changjian, was beneficially interested in approximately 0.01% of the entire issued share capital of Neptunus Bio-engineering, the Company's controlling shareholder, which in turn held directly and indirectly the beneficial interest in approximately 73.51% of the entire issued capital of the Company, of which 70.38% was directly held and 3.13% was indirectly held through Neptunus Oriental.

附註：

- (a) 董事會主席及海王生物第八屆董事局副主席、非獨立董事兼總裁張鋒先生實益擁有本公司控股股東海王生物全部已發行股本約0.05%之權益，而海王生物直接及間接實益擁有本公司全部已發行股本約73.51%之權益，其中70.38%為直接持有，3.13%經深圳海王東方投資有限公司（「海王東方」）間接持有。
- (b) 非執行董事于琳女士實益擁有本公司控股股東海王生物全部已發行股本約0.03%之權益，而海王生物直接及間接實益擁有本公司全部已發行股本約73.51%之權益，其中70.38%為直接持有，3.13%經海王東方間接持有。
- (c) 非執行董事沈大凱先生實益擁有本公司控股股東海王生物全部已發行股本約0.07%之權益，而海王生物直接及間接實益擁有本公司全部已發行股本約73.51%之權益，其中70.38%為直接持有，3.13%經海王東方間接持有。
- (d) 本公司職工代表監事、人力資源總監，海王長健副總經理、監事及人力資源負責人曹陽女士實益擁有本公司控股股東海王生物全部已發行股本約0.01%之權益，而海王生物直接及間接實益擁有本公司全部已發行股本約73.51%之權益，其中70.38%為直接擁有，3.13%經海王東方間接擁有。

Save as disclosed above, as at 30 June 2021, none of the Directors, supervisors or chief executive of the Company nor their respective associates held any interests or short positions in the shares, underlying shares or debentures of the Company or any of its associated corporations (within the meaning of Part XV of the SFO), which were required to be notified to the Company and the Stock Exchange pursuant to Part XV of SFO, or were required, pursuant to section 352 of the SFO to be and were recorded in the register to be kept by the Company, or were required, pursuant to Rule 5.46 to Rule 5.67 of the GEM Listing Rules, to be notified to the Company and the Stock Exchange.

SHARE OPTION SCHEME, CONVERTIBLE SECURITIES AND WARRANTS

Up to 30 June 2021, the Company and its subsidiaries have neither adopted any share option scheme nor granted any option, convertible securities, warrants or other similar rights.

DIRECTORS' AND SUPERVISORS' SHARE OPTIONS, WARRANTS OR CONVERTIBLE BONDS

At any time during the Reporting Period, none of the Directors or supervisors of the Company or their respective spouse or minor children were granted any share options, warrants or convertible bonds of the Company, its subsidiaries or associated corporation.

SUBSTANTIAL SHAREHOLDERS' INTERESTS IN SHARES AND UNDERLYING SHARES

So far as the Directors and supervisors of the Company are aware, as at 30 June 2021, the interests and/or short positions held by shareholders (not being a Director, a supervisor or a chief executive of the Company) in shares or underlying shares of the Company which were recorded in the register required to be kept by the Company pursuant to Section 336 of the SFO or had otherwise notified to the Company were as follows:

除上文披露者外，於二零二一年六月三十日，本公司董事、監事或最高行政人員或彼等各自之聯繫人士概無於本公司或其任何相聯法團(定義見證券及期貨條例第十五部)的股份、相關股份或債權證中擁有須根據證券及期貨條例第十五部知會本公司及聯交所之權益或淡倉，或須根據證券及期貨條例第352條須由本公司存備之登記冊將記錄及已記錄之權益或淡倉，或根據GEM上市規則第5.46條至5.67條之規定而須知會本公司及聯交所之權益或淡倉。

購股權計劃、可轉換證券及認股權證

截至二零二一年六月三十日，本公司及其附屬公司未曾採納任何購股權計劃，亦無授出任何購股權、可轉換證券、認股權證或其他類似權利。

董事及監事的購股權、認購權證或可換股債券

於報告期間內任何時間，本公司任何董事或監事或彼等各自的配偶或未成年子女概無獲授任何本公司，其附屬公司或相聯法團的購股權、認股權證或可換股債券。

主要股東於股份及相關股份的權益

據本公司董事及監事所知，於二零二一年六月三十日，股東(並非本公司董事、監事或最高行政人員)所持根據證券及期貨條例第336條須由本公司備存之登記冊所記錄的本公司股份或相關股份或以其他方式知會本公司之任何權益及/或淡倉如下：

Long positions in the shares of the Company:

於本公司股份之好倉：

Name of Substantial Shareholder	Capacity	Number of domestic shares held	Approximate percentage of all the domestic shares	Approximate percentage of the Company's issued share capital 佔本公司已發行股本的概約百分比
主要股東名稱	身份	持有內資股股份數目	佔所有內資股的概約百分比	
Neptunus Bio-engineering (Note (a)) 海王生物(附註(a))	Beneficial owner 實益擁有人	1,181,000,000	94.33%	70.38%
	Interest in controlled corporation 受控制法團權益	52,464,500	4.19%	3.13%
Bank of Changsha Co., Ltd. – Guangzhou Branch (Note (a)) 長沙銀行股份有限公司廣州分行 (附註(a))	Person having a security interest in shares 持有股份的保證權益的人	1,181,000,000	94.33%	70.38%
Shenzhen Neptunus Group Company Limited (“Neptunus Group”) (Note (b)) 深圳海王集團股份有限公司 (「海王集團」)(附註(b))	Interest in controlled corporation 受控制法團權益	1,233,464,500	98.52%	73.51%
Shenzhen Neptunus Holding Group Company Limited (“Neptunus Holding”) (previously known as “Shenzhen Yinhetong Investment Company Limited”) (Note (c)) 深圳海王控股集團有限公司 (「海王控股」(前稱「深圳市銀河通投資有限公司」)(附註(c))	Interest in controlled corporation 受控制法團權益	1,233,464,500	98.52%	73.51%
Mr. Zhang Si Min (Note (d)) 張思民先生(附註(d))	Interest in controlled corporation 受控制法團權益	1,233,464,500	98.52%	73.51%

Notes:

附註：

(a) Neptunus Bio-engineering was deemed to be interested in the 52,464,500 domestic shares of the Company held by Neptunus Oriental as the entire issued share capital of Neptunus Oriental was beneficially owned by Neptunus Bio-engineering. Neptunus Bio-engineering was also directly interested in 1,181,000,000 domestic shares of the Company. Therefore, Neptunus Bio-engineering was directly and indirectly interested in 1,233,464,500 domestic shares of the Company.

(a) 由於海王生物實益擁有海王東方全部已發行股本的權益，而海王東方擁有本公司52,464,500股內資股股份的權益，因此海王生物被視為擁有由海王東方持有的本公司52,464,500股內資股股份的權益。同時海王生物直接持有本公司1,181,000,000股內資股股份的權益，因此海王生物被視為直接及間接擁有本公司1,233,464,500股內資股股份的權益。

On 25 March 2021, Neptunus Bio-engineering has pledged 1,181,000,000 domestic shares in the Company to Bank of Changsha Co., Ltd – Guangzhou Branch as a security of a loan provided by Bank of Changsha Co., Ltd – Guangzhou Branch. Therefore, Bank of Changsha Co., Ltd. – Guangzhou Branch was deemed to be interested in 1,181,000,000 domestic shares of the Company. The said share pledge does not fall within the scope of Rule 17.19 of the GEM Listing Rules as it is not for the purpose to secure the Company's debt or to secure guarantees or other support of the Company's obligations.

- (b) Neptunus Group was deemed to be interested in the 1,233,464,500 domestic shares of the Company, which relate to the same parcel of shares referred to in note (a) above, held by Neptunus Bio-engineering as Neptunus Group was beneficially interested in approximately 44.22% of the entire issued share capital of Neptunus Bio-engineering.
- (c) Neptunus Holding was deemed to be interested in 1,233,464,500 domestic shares of the Company, which relate to the same parcel of shares referred to in note (a) above, held by Neptunus Bio-engineering as Neptunus Holding was beneficially interested in approximately 59.68% of the entire issued share capital of Neptunus Group, which in turn was beneficially interested in approximately 44.22% of the entire issued share capital of Neptunus Bio-engineering.
- (d) Mr. Zhang Si Min ("Mr. Zhang") was deemed to be interested in 1,233,464,500 domestic shares of the Company, which relate to the same parcel of shares referred to in note (a) above, held by Neptunus Bio-engineering as Mr. Zhang was beneficially interested in 70% of the entire issued share capital of Neptunus Holding and the entire issued share capital of Shenzhen Haihe Investment and Development Company Limited ("Haihe"), which in turn was beneficially interested in approximately 59.68% and 20% of the entire issued share capital of Neptunus Group respectively. Neptunus Group was beneficially interested in approximately 44.22% of the entire issued share capital of Neptunus Bio-engineering.

Save as disclosed above, the Directors and supervisors of the Company are not aware of any other persons (except the Directors, supervisors or chief executive of the Company) who held any interests or short positions in the shares or underlying shares of the Company as recorded in the register required to be kept by the Company pursuant to section 336 of the SFO as at 30 June 2021.

PURCHASE, SALE OR REDEMPTION OF THE LISTED SECURITIES OF THE COMPANY

The Company and its subsidiaries did not purchase, redeem or sell any of the Company's listed securities during the Reporting Period. The Company and its subsidiaries also did not redeem, purchase or cancel any of their redeemable securities.

COMPETING INTERESTS

On 21 August 2005, Neptunus Bio-engineering, the controlling shareholder of the Company, entered into an agreement with the Company containing undertakings relating to non-competition and preferential rights of investments (the "Non-Competition Undertakings"), pursuant to which Neptunus Bio-engineering had undertaken to the Company and its associates that, inter alia, as long as the securities of the Company are listed on GEM (previously known as Growth Enterprise Market):

於二零二一年三月二十五日，海王生物以1,181,000,000股本公司內資股作為向長沙銀行股份有限公司廣州分行借貸的抵押。因此，長沙銀行股份有限公司廣州分行被視為擁有海王生物持有的本公司1,181,000,000股內資股股份的權益。由於上述股份質押並非用於擔保本公司之債務或擔保本公司之保證或其他支持，因此上述股份質押不屬於GEM上市規則第17.19條之範疇。

- (b) 由於海王集團實益擁有海王生物全部已發行股本約44.22%的權益，因此海王集團被視為擁有由海王生物持有的本公司1,233,464,500股內資股股份的權益，與上文附註(a)所述同一筆股份相關。
- (c) 由於海王控股實益擁有海王集團全部已發行股本約59.68%的權益，而海王集團實益擁有海王生物全部已發行股本約44.22%的權益，因此海王控股被視為擁有由海王生物持有的本公司1,233,464,500股內資股股份的權益，與上文附註(a)所述同一筆股份相關。
- (d) 由於張思民先生（「張先生」）實益擁有海王控股全部已發行股本70%的權益及深圳市海合投資發展有限公司（「海合」）全部已發行股本的權益，而海王控股及海合分別實益擁有海王集團全部已發行股本約59.68%和20%的權益，而海王集團實益擁有海王生物全部已發行股本約44.22%的權益，因此張先生被視為擁有由海王生物持有的本公司1,233,464,500股內資股股份的權益，與上文附註(a)所述同一筆股份相關。

除上文所披露者外，於二零二一年六月三十日，本公司董事或監事概不知悉有任何其他人士（本公司董事、監事或最高行政人員除外）於本公司之股份或相關股份中，擁有根據證券及期貨條例第336條須由本公司備存之登記冊所記錄之權益或淡倉。

購買、出售或贖回本公司之上市證券

於報告期間，本公司及其附屬公司並無購買、贖回或出售本公司任何上市證券。本公司及其附屬公司並無贖回、購回或註銷其可贖回證券。

競爭權益

本公司控股股東海王生物與本公司於二零零五年八月二十一日訂立有關不競爭承諾及優先投資權的協議（「不競爭承諾」）。根據該協議，海王生物向本公司及其聯繫人承諾，（其中包括）只要本公司的證券仍於GEM（前稱「創業板」）上市：

1. it will not, and will procure its associates not to, whether within or outside the PRC, directly or indirectly (other than those indirectly held as a result of the equity interest in any listed company or its subsidiaries), participate in or operate any business in whatever form, or produce any products, (the usage of which is the same as or similar to that of the products of the Company) which may constitute direct or indirect competition to the business operated by the Company from time to time; and
2. it will not, and will procure its associates not to hold any interest, whether within or outside the PRC, in any company or organization (directly or indirectly, other than indirectly held as a result of its equity interest in any listed company or its subsidiaries) when the business of such company or entity will (or may) compete directly or indirectly with the business of the Company.

Pursuant to the Non-Competition Undertakings, at a time when the Non-Competition Undertakings are subsisting, whenever Neptunus Bio-engineering or any its associates enter into any negotiations, within or outside the PRC, in relation to any new investment project which may compete with the existing and future business of the Company, the Company shall have a preferential right of investment in such new investment projects.

Neptunus Bio-engineering has confirmed with the Company that it has complied with the Non-Competition Undertakings during the Reporting Period.

CODE OF CONDUCT REGARDING SECURITIES TRANSACTIONS BY DIRECTORS

During the Reporting Period, the Company has adopted a code of conduct regarding securities transactions by Directors on terms no less exacting than the “required standard of dealings” as set out in Rules 5.48 to 5.67 of the GEM Listing Rules. Having made specific enquiry of all the Directors, all the Directors confirmed that they have complied with the “Required Standard of Dealings” and the Company’s code of conduct regarding Director’s securities transactions.

1. 其將不會，並將促使其聯繫人不會以任何形式直接或間接在中國境內或境外參與或經營與本公司不時經營的業務構成直接或間接競爭的任何業務或生產任何用途與本公司產品相同或類似的產品（惟因持有任何上市公司或其附屬公司之股權而間接持有之業務則除外）；及
2. 其將不會，並將會促使其聯繫人不會在中國境內或境外（直接或間接）於其業務將（或有可能）與本公司業務產生直接或間接競爭的該等公司或機構中擁有任何權益，惟因持有任何上市公司或其附屬公司股權而間接持有者則除外。

根據不競爭承諾，於不競爭承諾的有效期內，如海王生物或其聯繫人在中國境內或境外就與本公司現有及將來業務構成競爭的新投資項目進行磋商，本公司將獲得優先投資該等新投資項目的權利。

海王生物已向本公司確認其於報告期間已遵守不競爭承諾。

董事進行證券交易之操守守則

於報告期間內，本公司採納一套條款不低於GEM上市規則第5.48至5.67條所載的「交易必守標準」的董事進行證券交易的操守守則。經向全體董事作出具體查詢後，全體董事確認，彼等於報告期間內，已遵守「交易必守標準」以及本公司之董事進行證券交易的操守守則。

AUDIT COMMITTEE

The Company established an Audit Committee (the "Audit Committee") on 21 August 2005. The primary duties of the Audit Committee are to review the Company's annual report and financial statements, half-yearly reports and quarterly reports, and to provide suggestions and opinions thereon to the Board. In addition, the Audit Committee members will also meet with the management to review the accounting principles and practices adopted by the Company and to discuss matters relating to the auditing, internal control system and financial reporting process of the Company. The Audit Committee comprises one non-executive Director, namely Ms. Yu Lin and two independent non-executive Directors, namely Mr. Yick Wing Fat, Simon and Mr. Poon Ka Yeung. Mr. Yick Wing Fat, Simon is the chairman of the Audit Committee.

The Audit Committee has reviewed the unaudited condensed consolidated results of the Group for the Reporting Period.

COMPLIANCE WITH THE CORPORATE GOVERNANCE CODE

As the Directors are aware, during the Reporting Period, the Company has complied with the requirements under the "Corporate Governance Code and Corporate Governance Report" set out in Appendix 15 of the GEM Listing Rules. The Board will continue to enhance the standard of corporate governance of the Company to ensure that the Company will operate its business in an honourable and responsible manner.

EVENTS AFTER THE REPORTING PERIOD

There are no important events affecting the Group which have occurred after the end of the Reporting Period and up to the date of this report.

On behalf of the Board

Shenzhen Neptunus Interlong Bio-technique Company Limited*

Zhang Feng

Chairman

Shenzhen, the PRC, 12 August 2021

As at the date of this report, the executive Directors are Mr. Zhang Feng and Mr. Huang Jian Bo; the non-executive Directors are Mr. Zhang Yi Fei, Ms. Yu Lin, Mr. Shen Da Kai and Mr. Xu Yan He; and the independent non-executive Directors are Mr. Yick Wing Fat, Simon, Mr. Poon Ka Yeung and Mr. Zhang Jian Zhou.

* For identification purpose only

審核委員會

本公司已於二零零五年八月二十一日成立審核委員會(「審核委員會」)。審核委員會之主要職責包括審核本公司的年報及財務報表、半年度報告及季度報告，以及就此向董事會提供意見及建議。此外，審核委員會成員與管理層一起檢討本公司所採納的會計準則及常規，商討審核、內部監控制度和財務申報程序事宜。審核委員會包括一位非執行董事于琳女士及兩位獨立非執行董事易永發先生及潘嘉陽先生。易永發先生為審核委員會主席。

審核委員會已經審閱本集團於報告期間之未經審核簡明綜合業績。

遵守企業管治守則

據董事所知，本公司於報告期間一直遵守GEM上市規則附錄十五《企業管治守則》及《企業管治報告》所載的規定。董事會將繼續提升本公司的企業管治標準，確保本公司以誠實負責的態度經營業務。

報告期後事項

於報告期間結束後直至本報告日期，並未發生影響本集團之重要事項。

代表董事會

深圳市海王英特龍生物技術股份有限公司

主席

張鋒

中國深圳市，二零二一年八月十二日

於本報告日期，執行董事為張鋒先生及黃劍波先生，非執行董事為張翼飛先生、于琳女士、沈大凱先生及徐燕和先生，獨立非執行董事為易永發先生、潘嘉陽先生及章劍舟先生。

* 僅供識別

